Published in final edited form as:

Curr Drug Targets. 2017 ; 18(7): 826–843. doi:10.2174/1389450116666150825110532.

Innate and Adaptive Immune Responses in Chronic HCV infection

Lynn B. Dustin

University of Oxford, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, Kennedy Institute of Rheumatology, Peter Medawar Building for Pathogen Research, South Parks Road, Oxford OX1 3SY, United Kingdom

Abstract

Hepatitis C virus (HCV) remains a public health problem of global importance, even in the era of potent directly-acting antiviral drugs. In this chapter, I discuss immune response to acute and chronic HCV infection. The outcome of HCV infection is influenced by viral strategies that limit or delay the initiation of innate antiviral responses. This delay may enable HCV to establish widespread infection long before the host mounts effective T and B cell responses. HCV's genetic agility, resulting from its high rate of replication and its error prone replication mechanism, enables it to evade immune recognition. Adaptive immune responses fail to keep up with changing viral epitopes. Neutralizing antibody epitopes may be hidden by decoy structures, glycans, and lipoproteins. T cell responses fail due to changing epitope sequences and due to exhaustion, a phenomenon that may have evolved to limit immune-mediated pathology. Despite these difficulties, innate and adaptive immune mechanisms do impact HCV replication. Immune-mediated clearance of infection is possible, occurring in 20–50% of people who contract the disease. New developments raise hopes for effective immunological interventions to prevent or treat HCV infection.

1. Introduction

Although estimates vary, it is believed that between 130 million and 200 million people worldwide are persistently infected with the hepatitis C virus, HCV (1–3). There is not yet an approved prophylactic vaccine. HCV is transmitted through percutaneous contact with infected blood. In most developed countries, blood screening has virtually eliminated the risk of infection through blood and blood products, but HCV transmission remains high in developing countries and also among people who inject drugs. Occupational, nosocomial, and vertical transmission are all observed, and sexual transmission of HCV may occur in some settings. Acute HCV infection may be asymptomatic or the symptoms may be nonspecific; thus, people may not know they are infected until many years later, when significant liver damage has occurred (4). Over 20–30 years, 15–30% of those chronically infected with HCV may develop long-term complications including cirrhosis; some of those can go on to develop hepatocellular carcinoma and/or end-stage liver disease (4, 5). HCV

Correspondence: Lynn.Dustin@Kennedy.ox.ac.uk.

The author declares no competing financial interests.

infection is now the leading indication for liver transplantation (6). Patients who harbor HCV at the time of transplantation experience recurrent infection of the grafted liver, frequently leading to accelerated fibrosis and cirrhosis (6).

Deaths from HCV now outstrip those from HIV infection in the developed world, and HCV infection increases mortality from other causes (7, 8). HCV complicates the outcome and treatment of other infectious diseases, and other infectious diseases complicate HCV pathogenesis and treatment. Thus, an estimated 20–30% of people with HIV infection worldwide are co-infected with HCV. HIV/HCV co-infection is associated with higher HCV viral loads, increased HCV chronicity, reduced response to anti-HCV therapy, and accelerated liver damage compared to HCV-mono-infection. Co-infected patients are also more likely to suffer kidney and neurocognitive disease than are HIV-mono-infected patients, and HCV co-infection can impact antiretroviral therapy for HIV (5, 9, 10). Hepatitis B virus (HBV) can exacerbate liver disease due to persistent HCV infection, while super-infection with HCV can exacerbate liver disease due to chronic HBV infection (11). Co-infection with HCV and liver-tropic parasites such as *Schistoma mansoni* may also lead to more rapid and severe liver disease than either pathogen alone (12). The immunopathogenic mechanisms of co-infection are still poorly understood and require additional study.

The landscape for HCV treatment is changing rapidly, and new directly-acting antiviral (DAA) drugs offer the hope that most patients who are treated can be cured (5, 13–16). At this time, however, most patients have not been either diagnosed or treated (17, 18). Among the numerous barriers to treatment are ignorance of infection status, uneven healthcare access, concern about side effects, and high drug prices (19). In addition, antiviral treatment will not immediately reverse liver disease in the millions of patients who have been infected for decades and in whom the burden of HCV-related liver disease will continue to increase dramatically in the coming years (20).

2. The goal of a vaccine

The availability of DAAs will not eliminate HCV as a global health problem. Ultimately, an effective, widely available vaccine will be needed to curb ongoing HCV transmission (21–23). While most HCV-infected patients progress to chronic hepatitis with persistent viremia, a significant minority (20–50%) of patients mount a successful immune response to HCV, resulting in **spontaneous resolution** of infection; recovery rates differ depending on factors such as age, race, sex, and genetics (5, 24–28). Thus, immune mediated control is possible. Can we stimulate a successful immune response, and thus protection from HCV persistence, with a vaccine? Several challenges have hindered vaccine development work to date. HCV presents extensive genetic diversity: there are seven major genotypes, whose nucleotide sequences differ from each other by 30% or more, and dozens of subtypes differing by at least 15% (29). Recent work has demonstrated that T cell immunity to HCV is likely to be genotype or even isolate-specific, even in subjects who spontaneously resolve infection (30). The inter-genotype and inter-subtype genetic diversity is compounded by HCV's rapid evolution within each infected host. Also important, the correlates of protection from HCV

infection are still incompletely understood. Discouragingly, those fortunate people who clear HCV infection without treatment have incomplete protection from re-infection (31–33).

3. Hepatitis C virus, antiviral therapy, and sites of replication

HCV is an enveloped RNA virus in the family Flaviviridae. Its genomic structure and replication mechanisms are detailed in several excellent recent reviews (16, 34–36). HCV has a single-stranded, positive sense RNA genome of approximately 9.6 kb (Figure 1). The RNA lacks 5' cap and 3' poly-A structures; translation occurs via an internal ribosomal entry site (IRES) that hijacks the ribosome to enable cap-independent protein translation. HCV RNA encodes a single polyprotein of approximately 3010 amino acids, which is processed co- and post-translationally by host and viral proteases to release ten mature proteins. These proteins are Core (capsid), the envelope glycoproteins E1 and E2, and seven non-structural proteins: p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B. The assembled virus is believed to incorporate HCV RNA plus core, E1, and E2 (37); p7 and NS2 are not required for HCV RNA replication but are required for virus assembly and egress; NS3–5B together make up the viral replicase while also contributing to assembly (36). RNA replication proceeds through a negative-sense RNA template. HCV's NS5B RNA-dependent RNA polymerase lacks proofreading activity. As a result, the viral RNA changes rapidly and circulates within each infected host as a quasispecies—a swarm of related viral sequences. This availability of a diverse pool of viral sequences provides the raw material for rapid evolution under selection from host immune pressures and antiviral drugs.

Until recently, the gold standard for antiviral therapy involved prolonged treatment (24–48 weeks) with injected, PEGylated IFN α preparations plus the nucleoside analog, ribavirin. The treatment was difficult to tolerate and often ineffective. DAAs have dramatically changed the landscape for HCV patients, but the new drugs are expensive. DAAs target key steps in HCV replication and assembly. A detailed discussion of this topic is beyond the scope of this chapter, but the reader is referred to a number of excellent recent reviews (5, 15, 16). The first DAAs that came to market targeted the NS3–4A protease, blocking cleavage of the polyprotein and perhaps also of cellular targets. These first-generation DAAs, including Boceprevir and Telaprevir, were most effective when administered in combination with PEGylated IFN α and ribavirin; they were not equally effective in all HCV genotypes; and viral resistance to these drugs could be achieved with a small number of mutations (this is termed a low **barrier to resistance**). Subsequent generations of NS3–4A protease inhibitors are expected to have broader HCV genotype coverage and a higher genetic barrier to resistance. Development of drugs targeting other HCV proteins has raised hopes for the availability of an all-oral, IFN-free treatment regimen. Drugs that target NS5A (for example, Daclatasvir and Ledipasvir) have high potency, but some have a relatively low barrier to resistance. Drugs that target the NS5B polymerase include nucleoside analogs such as Sofosbuvir, which block polymerase activity in all HCV genotypes, and non-nucleoside drugs that may act by allosteric mechanisms. The non-nucleoside drugs target specific HCV genotypes. Combinations of these drugs act synergistically to inhibit HCV replication. All-oral drug combinations targeting 2 or 3 viral targets have shown extremely high potency in clinical trials. Additional drugs, targeting host factors required for HCV

replication, are also in development. Host targets of these drugs include the microRNA miR-122, cyclophilin, and molecules required in HCV entry (16).

The primary site of HCV replication is the hepatocyte. Replication in blood cells and other tissues, if it occurs, is likely to be limited by several factors; these other cell types have not yielded robust and reproducible in vitro systems for HCV study. Importantly, HCV replication is dependent on the liver-specific miRNA, miR-122 (38–40). HCV particle assembly is tightly linked to host lipid and lipoprotein biosynthetic pathways (36, 37), and circulating HCV associates with host lipoproteins. Infectious HCV behaves as a lipo-viral particle (36, 41, 42) that takes advantage of hepatocyte lipoprotein capture mechanisms to gain entry into susceptible cells (42, 43). Many of the host factors involved in HCV entry are not expressed at significant levels in blood cells (44). Virus may be taken into many cell types without productive infection. Examination of biopsy material shows that infected hepatocytes are distributed in clusters of 4–50 cells (45), suggesting that HCV may spread efficiently from an infected “founder” cell to its closest neighbors (45–47).

4. Detecting and responding to HCV: Innate antiviral responses

Virus replication generates numerous pathogen-associated molecular patterns (**PAMPs**), and these in turn stimulate IFN and IFN-stimulated gene (**ISG**) expression. ISGs mediate numerous direct antiviral effects. IFNs, ISGs, inflammatory cytokines, and other signals derived from infected cells contribute to the initiation and regulation of adaptive immune responses. HCV, like many viral pathogens, has evolved strategies to blunt the innate antiviral response (48, 49). Thus, HCV RNA replication takes place in specialized, enclosed structures that may hide PAMPs from cellular detection (36). As discussed in this section, the viral NS3-4A protease specifically targets some proteins involved in virus detection. Other viral strategies to block IFN induction and signaling have also been proposed (reviewed in (50–52)). However, as discussed below, despite HCV’s ability to disable virus-sensing mechanisms within infected cells, antiviral pathways are initiated soon after virus infection and persist in the chronically-infected liver.

4.1. Recognition of viral RNA

HCV RNA has a phosphorylated 5′ end and a poly U/UC sequence near its 3′ end. These PAMPs together facilitate HCV RNA recognition by the cytosolic RNA binding protein, retinoic acid induced gene-I (**RIG-I**) (53–56). RNA-bound RIG-I triggers ubiquitination reactions and the formation of signaling complexes that ultimately activate the mitochondrial antiviral signaling protein (**MAVS**) (57). MAVS resides on intracellular membranes of mitochondria, mitochondrial-associated membranes near the endoplasmic reticulum, and peroxisomes. When activated, MAVS forms prion-like aggregates which recruit additional ubiquitin ligase activities (58). These ubiquitin ligases catalyze the production of K63 polyubiquitin chains, which facilitates protein-protein interactions that then activate the downstream interferon response factor-3 (**IRF3**) and **NFκB** pathways required for IFN induction (58, 59) (Figure 2A). Of interest, the various subcellular locations of MAVS are associated with distinct downstream activities (48, 60). Peroxisome-associated MAVS may be key to HCV recognition in hepatocytes because of its unique ability to stimulate **IFNλ**.

gene expression (60). HCV's NS3-4A protease cleaves MAVS, releasing it from subcellular membranes, and can thereby prevent MAVS-mediated induction of IFN expression in HCV-infected cells (61, 62). MAVS cleavage has been observed in the HCV-infected liver (63, 64). However, RIG-I can recognize incoming viral RNA as it emerges from the nucleocapsid—before any viral replication or genome translation (65). This early recognition may explain, in part, why HCV-infected cells mount innate responses despite the presence of cleaved MAVS.

HCV RNA folds into complex structures featuring numerous stem-loops that can also act as PAMPs (Figure 1). These include the internal ribosomal entry site (IRES) near the 5' end of the HCV genome. Innate recognition of this PAMP may paradoxically reduce antiviral responses (66). As early as 2 hours post infection, HCV IRES binding to protein kinase R (PKR) reportedly stimulates a signaling cascade involving MAVS, TRAF3, and IRF3, but not RIG-I, to induce IFN- β and ISG expression (67). PKR inhibits host cell protein translation by phosphorylating and inactivating the eukaryotic translation initiation factor, eIF2 α . Such inhibition may reduce the translation of antiviral ISGs, without inhibiting the (eIF2 α -independent) IRES-mediated translation of HCV RNA (66, 68). By activating PKR, HCV may also trigger ISG15 expression (67). Higher ISG15 levels are associated with poor response to IFN-based HCV therapies (69, 70), and ISG15 could promote HCV replication by interfering with the ubiquitination reactions needed for RIG-I signaling (67).

HCV RNA replication entails production of a double-stranded RNA (dsRNA) intermediate; dsRNA binds and activates the endosomal Toll-like receptor 3 (TLR3). TLR3 engagement stimulates IFN gene expression via the adaptor molecule, TIR-containing adaptor inducing IFN β (TRIF). TRIF signals via ubiquitin ligase-dependent pathways to activate IRF3 and NF κ B (reviewed in (49, 59, 71)) (Figure 2B). HCV's NS3-4A protease may disable TLR3 signaling by cleaving TRIF, potentially disabling this pathway in infected cells (49, 72). Some questions remain about the role of TLR3, and of TRIF cleavage, in innate HCV recognition. TLR3's RNA binding domains are localized in the endosomes rather than the cytosol; thus, they may not have access to HCV PAMPs within the infected cell. TLR3 may recognize HCV RNA taken up from neighboring infected cells or possibly in a cell-autonomous manner through autophagy. It is not clear whether or how NS3-4A-mediated TRIF cleavage affects the detection of HCV RNA by bystander or immune cells, since few if any of these cells would be infected—therefore, these cells are unlikely to express NS3-4A.

4.2 IFNs and ISGs

Despite the cleavage of MAVS and TRIF, it is clear that HCV stimulates innate antiviral pathways during acute and chronic infection. In acutely infected chimpanzees, hepatic ISG expression coincides with partial control of HCV replication (73–75). The sources and types of the IFN involved were not determined in these studies (73–76). Importantly, hepatocytes can express both type I (α/β) and type III (λ) IFNs, and can respond to these as well as to type II (γ) IFN.

Recent studies have shown that hepatocytes preferentially express type III IFNs in response to HCV infection, and that this expression is observed even in the presence of MAVS cleavage (77–81). HCV-infected primary liver cells produce IFN λ protein at levels sufficient

to limit HCV replication (77, 81). Single nucleotide polymorphisms (SNPs) in and near the type III IFN genes are associated with the outcome of primary HCV infection (82, 83), IFN α -based antiviral therapy (84–88), and quantitative variation in ISG expression in vivo (89, 90) and in vitro (80). The type III IFN receptor, IFNLR, is preferentially expressed in epithelial tissues including the liver parenchyma (reviewed in (87)). Type III IFNs are encoded in a cluster on the long arm of human chromosome 19 (reviewed in (87, 88)). The genes are *IFNL1*, encoding the protein IFN λ 1 (previously IL-29); *IFNL2*, encoding the protein IFN λ 2 (previously IL-28A), *IFNL3*, encoding IFN λ 3 (previously IL-28B), and the more recently discovered *IFNL4*, encoding IFN λ 4.

How does polymorphism in this region influence HCV infection? Higher intrahepatic ISG expression at baseline is paradoxically associated with reduced likelihood of response to IFN α -based therapeutic regimens (91–93). The non-protective SNPs are associated with relatively higher ISG expression in patients with HCV infection (89), but not in healthy subjects (90). Because the important SNPs were close to the *IFNL3* gene, initial studies focused on their effects on *IFNL3* mRNA expression (85, 86, 89, 92, 94) or stability (95). Results were inconsistent (88). In 2013, researchers identified a novel gene, now termed *IFNL4*, in the IFNL3 region; this gene is transiently expressed in human hepatocytes following stimulation with a double-stranded RNA PAMP (96). The protective *IFNL3*/IL28B SNPs are in linkage disequilibrium with polymorphisms in the *IFNL4* gene. Specifically, a protective TT allele at rs368234815 disrupts the *IFNL4* open reading frame, abolishing protein expression, while the non-protective *IFNL4* G allele at this site results in an intact open reading frame (96). The *IFNL4* G allele is believed to be the ancestral allele (88). The high frequency of the TT allele in some populations suggests that these populations are descended from survivors of some (presumably infectious) event that selected against expression of IFN λ 4 (88). The non-protective *IFNL4* G allele is associated with development of persistent HCV infection (97). A different *IFNL4* polymorphism, encoding a variant with diminished IFN activity, is also associated with improvements in spontaneous and treatment-induced clearance (98). *IFNL4* is more distantly related to the other members of the *IFNL* gene family, but may have a similar protein structure (99) and has demonstrable antiviral activity (99). Despite the strong evidence that ability to express IFN λ 4 contributes to development of persistent HCV infection, increased baseline ISG expression, and reduced efficacy of IFN α -based antiviral therapy, the mechanisms by which IFN λ 4 may influence these disparate outcomes remain uncertain.

In vivo, IFNs produced by other cell types also undoubtedly contribute to the hepatic ISG response. Thus, dendritic cells (DCs) patrolling the liver may produce type I (100–102) and type III (103) IFNs following recognition of HCV RNA in exosomes or debris from infected hepatocytes. Recent work suggests that a very small subset of myeloid DCs expressing BDCA3/CD141 may play a key role in production of type III IFNs in response to HCV or debris from infected cells; type III IFN production by these cells is dependent on TLR3 signaling (104–106). Liver endothelial cells may also produce IFNs and amplify local IFN responses following detection of virus or debris (107). Natural killer cells and T cells also play key roles, as discussed in later sections of this chapter. IFN γ derived from activated T cells, in particular, is associated with viral clearance.

Which ISGs are expressed, and how do they impact HCV replication? There are more than 300 ISGs, mediating diverse antiviral functions as discussed in several excellent recent reviews (49, 76, 108–110). Although the type I and type III IFNs signal through distinct receptors, they induce similar sets of ISGs (albeit with somewhat different kinetics (87, 111, 112)). Among the ISGs expressed following HCV infection, several have potential activity against HCV (49, 77, 80, 113). These include oligoadenylate synthetases (OAS1 and OAS2), which synthesize 2'-5' oligoadenylate that can, in turn, activate RNase L to cleave HCV RNA; ISG20, an exonuclease; IFIT1 (ISG56), which may inhibit HCV IRES-mediated polyprotein translation; IRF1, IRF7, STAT1, RIG-I, and MDA-5, which may amplify IFN expression or response; RSAD2 (viperin) which may act on HCV through its interaction with lipid droplets (114); IFITM1 and IFITM3, which may act to inhibit viral entry and fusion. While specific individual ISGs are able to reduce HCV replication *in vitro*, multiple ISGs likely operate synergistically within infected cells.

4.3 Why doesn't innate immunity clear HCV infection?

Importantly, the cycle of virus entry, virus detection, ISG induction, and innate antiviral response continues throughout chronic infection. HCV and ISG RNA can be found in the same cells *in vitro* (80) and during chronic infection *in vivo* (46) (but see (47)). The observation that ISG expression in the liver correlates with a sharp drop in viremia during acute HCV infection (73–75) strongly suggests that innate mechanisms control HCV infection *in vivo*. These observations raise the question of why endogenous IFNs and ISGs don't cure HCV infection. Indeed, higher ISG expression before the start of therapy is associated with a poor outcome in IFN-based antiviral therapy (91–93). High intrahepatic ISG expression is now believed to correlate with polymorphisms in the IFN λ locus (89). Stochastic variability in IFN induction and/or responsiveness between cells may provide HCV with a continuous supply of susceptible cells with reduced ISG expression (80, 115, 116). Other mechanisms may also contribute. HCV-activated PKR could shut down translation of host cell ISG mRNAs without affecting HCV translation (68); to learn whether this mechanism operates in the infected liver, it will be necessary to define, at the protein level, which ISGs are expressed in infected cells and neighboring uninfected cells. Researchers have proposed that HCV proteins, notably core, E2, and NS5A, may interfere with IFN signal transduction or block specific ISG functions (reviewed in (48–50)); of note, however, many of these studies have depended on overexpression of single HCV proteins in transfected cells, and have not been confirmed in infected cells or in patients. Finally, reduced HCV replication may be advantageous for a persisting virus because it limits antigen display and therefore T cell recognition, thus preventing development of fulminant liver disease and extending host survival.

5. Innate immune cells in chronic HCV infection

The liver environment is rich in cells that bridge innate and adaptive immunity. Here, I will touch briefly on natural killer (NK) cells, dendritic cells (DCs), and cells in the monocyte-macrophage lineage. For a recent review on these and other innate cells in the liver, the reader is referred to (117).

5.1 NK cells

NK cells are abundant in the liver in health and during HCV infection (118, 119). NK cell activation is mediated in part by integration of information from a diverse array of activating and inhibitory receptor-ligand pairs (120). Genetic polymorphisms in the numbers and types of these receptors, and their ligands, mandate that developing NK cells must be educated or “licensed” to function in each individual (120, 121). Of note, some genetic polymorphisms that affect NK cell activation thresholds are reported to correlate with spontaneous and treatment-induced clearance of HCV (122, 123).

NK cells are among the earliest immune responders to viral infection, but the roles of NK cells in control of HCV are still poorly understood (119). They may contribute to viral control through secretion of cytokines, including IFN α , IFN γ , and TNF α , that can drive ISG expression, inhibit viral replication, promote DC maturation, and promote release of chemokines that recruit lymphoid and inflammatory cells (reviewed in (50)). NK cells may also mediate direct lysis of infected hepatocytes, but it is not known whether this activity occurs in patients, how infected cells are recognized, or whether such lysis has a significant impact on viral loads. NK cells may modulate adaptive immune responses by killing antigen-presenting cells and activated CD4⁺ T cells (120); whether this mechanism operates during HCV infection is not yet known. Through early antiviral activities, NK cells may protect T cells from exhaustion due to high antigen levels (reviewed in (121)). NK cells are activated during acute HCV infection, arguing against reports that HCV envelope proteins inhibit NK cell function (119, 124, 125). In vitro studies also refute the hypothesis that HCV somehow inhibits NK cell function (126).

There is a great deal of literature describing possible alterations in NK cell phenotype, subset distribution, and function during HCV infection, but these reports are sometimes contradictory (119, 127, 128). Altered expression of specific activating and inhibitory receptors has been expressed in some studies, but the mechanisms of these alterations are not yet certain. Functional NK cell subsets include a CD56^{bright}/CD16^{negative} subset that produces IFN γ and a CD56^{dim}/CD16^{positive} subset that mediates cytotoxic activity. Altered ratios of cytotoxic to IFN γ -producing subsets have been reported in peripheral blood NK cells in patients with persistent HCV infection. Increased levels of a functionally deficient NK subset (CD56^{negative}/CD16^{positive}) are also reported. It is unclear whether altered NK cell subset distribution represents dysfunction, specific activation in the liver environment, or a protective mechanism that limits NK-mediated liver damage.

5.2. Dendritic cells (DCs)

DC subsets (129–131) influence the outcome of HCV infection through production of IFNs and other cytokines that directly affect viral replication and influence T cell activation, and through potent antigen presentation to T cells. Of the many DC subsets, three in particular have been studied for their role in HCV infection: plasmacytoid DCs (pDCs), which produce high levels of IFNs; myeloid or classical DCs (mDCs), which play essential roles in antigen presentation; and a minor population termed mDC2, identified by the expression of BDCA3/CD141, which may be especially potent IFN λ , producers (106). DCs may change their

phenotypes and functions in response to different signals, thus there may be some fluidity among DC subsets (131).

Recognition of distinct PAMPs drives DCs to produce different cytokines, and these in turn promote different downstream immune responses (reviewed in (131)). pDCs preferentially recognize HCV via TLR7 (which binds single-stranded RNA), and produce higher levels of type I IFNs. The mDC2 subset appears to preferentially recognize HCV via TLR3 sensing of double-stranded RNA, and to produce particularly high levels of type III IFNs. The IFNs can act on hepatocytes and also on myriad other cell populations. DCs activated through engagement of the endosomal nucleic acid receptors TLR3, TLR7, or TLR9 produce IL-12; this cytokine supports TH1 differentiation and subsequent competence to produce IFN γ . IL-18 and IL-27 from DCs can synergize with IL-12 to promote TH1 development. Other PAMPs, including those binding TLR2, induce IL-10, which supports TH2 differentiation. There are reports that various HCV structural and non-structural proteins stimulate TLR2 on DCs, resulting in functional changes (reviewed in (117)). Some PAMPs, notably those derived from fungi, can promote release of IL-6 and IL-23, which support TH17 differentiation. Some PAMPs induce production of IL-10, retinoic acid, and TGF- β , supporting Treg differentiation. DCs can also release IL-15, which supports T cell survival. Type I IFN, IL-12, and IL-15 derived from DCs support NK cell activation, cytotoxicity, and survival (117).

HCV's effects on DCs are controversial. Peripheral blood DCs are reduced in number in HCV patients (reviewed in (50, 117)), but this quantitative reduction is not accompanied by functional deficit (132–134). DCs may be reduced in the blood because of accumulation in the liver (135). Patients with HCV infection do not suffer from global immunological impairment, arguing against the notion that HCV exerts a broad inhibitory effect on DCs. Some groups report that DC function is impaired or cytokine production profiles altered in HCV patients (136–138). Cell culture-produced HCV was reported to inhibit IFN α production by DCs stimulated with TLR9 ligands (139); other studied functions were unaffected, and inhibition was independent of HCV infection or replicative capacity. Disruption of DC functions has been described in various vitro systems utilizing overexpression or high doses of individual HCV proteins (reviewed in (117)); the significance of these changes in vivo is not known. Arguing against an important role for HCV non-structural proteins within DCs, I would note that it is not clear that DCs support HCV infection. DCs do not express the full complement of entry factors required for infection of hepatocytes (44). The levels of HCV RNA associated with DCs in chronically infected patients are well below one RNA copy per cell (137, 140), suggesting that at most a minor population of patient DCs support any HCV replication. DC uptake of HCV for antigen presentation occurs independently of HCV entry factors (141). DCs may capture HCV (without productive infection) in part through the C-type lectin DC-SIGN (142, 143), perhaps permitting them to deliver HCV to susceptible cells.

An important role for DC activation and function is shown in prospective studies of people exposed to HCV through illicit drug use. Subjects who mounted a successful immune response, resulting in spontaneous resolution of infection, had reduced numbers of mature pDCs and increased evidence of mDC activation, including increased cytokine production in

response to a diverse array of TLR ligands, increased expression of the T cell costimulator CD86, and reduced expression of inhibitory ligands such as PD-L1 and PD-L2 (144).

5.3 Monocytes, macrophages, and Kupffer cells

Monocytes, macrophages, and Kupffer cells (macrophages resident in the hepatic sinusoids) are abundant in the liver and are thought to play key roles in hepatic inflammation (145). These cell types express a variety of receptors that can detect pathogens and PAMPs at the cell surface and following internalization (145). Receptors at the cell surface include DC-SIGN, mannose receptor, and scavenger receptors. Human Kupffer cells are reported to produce inflammatory cytokines, notably IL-1 β and IL-18, following interaction with HCV or HCV-infected cells (146–149). HCV replication is not required for this effect. The roles of IL-1 β and IL-18 in chronic infection are not yet well understood, but they may contribute to intrahepatic and systemic inflammation, and increase production of IFN γ by NK cells (148). Kupffer cells, monocytes, and macrophages in the liver can modulate inflammation, immunity, and fibrosis through release of a host of other cytokines, including IL-10, IL-6, IL-12, TNF α and TGF β , as well as reactive oxygen species (145). These cells may also present antigen to T cells; their expression of costimulatory ligands such as CD86, and co-inhibitory ligands including PD-L1, PD-L2, and galectin 9 may influence subsequent T cell activation and function (145).

6. T lymphocytes in HCV infection

T cells mediate both protective and pathological roles in HCV infection. Analysis of acute resolving infections suggests that T cells may control HCV infection both through IFN γ production and by killing infected cells. Spontaneous resolution of HCV infection follows the appearance in the liver of T cells expressing IFN γ (50, 74, 75, 150–153). In successful immune responses, these cells must target a broad array of HCV epitopes in order to reduce viral immune escape. These broadly-reactive T cell responses are sustained through spontaneous HCV clearance and for years afterward. In contrast, in infections that progress to chronicity, initial broadly directed T cell responses collapse (Figure 3). Both CD4⁺ and CD8⁺ T cell subsets are essential for resolution of infection, as demonstrated by studies in which chimpanzees that had previously cleared HCV were re-infected after depletion of one subset or the other (154, 155).

IFN γ stimulates an antiviral program in hepatocytes, inhibiting HCV replication without killing infected cells; this mechanism allows limited numbers of antigen-specific T cells to mediate control, and offers the advantage of hepatocyte survival (156). However, the data support a key role for T cell-mediated killing of infected hepatocytes. T cell perforin expression, and hepatocyte apoptosis, correlated with spontaneous clearance of HCV in experimentally infected chimpanzees (157). Unlike IFN γ -dependent mechanisms, cytolytic control of HCV replication is likely to depend on larger numbers of T lymphocytes (156). As discussed below, persistent HCV infection is associated with **exhaustion** of HCV-specific T cells. Cytolytic activity is lost early in the development of T cell exhaustion, while IFN γ production may persist (158). If cytolysis of infected hepatocytes is required for

resolution of infection, then loss of T cell proliferative capacity, associated with “stunned” HCV-specific T cells (159), could contribute to the low rate of spontaneous clearance.

Adaptive immunity exerts control over HCV infection even in persistent infection; thus, immunosuppressive therapy, immunodeficiencies, and HIV co-infection all exacerbate HCV-driven liver disease (4). Immunity to HCV re-infection is possible (31, 160). Unfortunately, however, even vigorous T cell responses after spontaneous clearance of HCV infection do not confer complete protection against subsequent challenge with homologous or heterologous HCV strains (161–163). Indeed, chimpanzees experimentally exposed to trace quantities of HCV showed induction of regulatory T cells and poor subsequent responses to HCV infection (164).

Immune responses to HCV are not always beneficial. While infected hepatocytes may have reduced lifespan (45, 165), HCV is not thought to be directly cytopathic. T cells, rather than virus, may be responsible for liver damage in acute infection (74, 166). In chronic infection, most of the inflammatory T cells infiltrating the liver are not even specific for HCV (167–169).

6.1. What happens to T cells in persistent HCV infection?

Immune responses to HCV are slow to develop even in infections that resolve without treatment (Figure 3). This delay may be due in part to HCV's effects on innate immune signaling, as discussed in the previous section. As HCV infection progresses to persistence, the initial, broadly directed HCV-specific CD4⁺ and CD8⁺ T cell response weakens. The number of epitopes targeted is reduced due to failure of epitope-specific T cell populations and to viral evolution. The waning of HCV-specific T cell function may be an adaptive response that reduces T cell-mediated tissue damage in conditions of persistent, high antigen load; reduced viral loads may permit T cells to recover their function (170).

6.2. CD4⁺ T cell failure

HCV-specific CD4⁺ T cell help is lost as infection persists, and this loss contributes to the decline in function of HCV-specific CD8⁺ T cells. The pathways leading to loss of CD4⁺ T cell help are still not understood (171). HCV-specific CD4⁺ T cells are observable during acute infections, even those that progress to chronicity (166, 172, 173). However, HCV-specific CD4⁺ T cells are scarce in established chronic infection (172, 174). Studies in mice with chronic viral infection have shown that activated NK cells may facilitate viral persistence and CD4⁺ T cell failure by killing responding CD4⁺ T cells (152, 175, 176). Whether such a mechanism contributes to loss of HCV-specific CD4⁺ T cells in humans is not yet known. HCV-specific CD4⁺ T cells have lower expression of the **IL-7 receptor alpha chain, CD127**, during infections that progress to chronicity compared to infections that resolve without treatment (177). Given the importance of IL-7 in memory T cell survival and turnover (178), loss of this signal may contribute to the disappearance of CD4⁺ T cell responses to HCV. Patients with chronically-evolving HCV infection were reported to have increased expression of a negative regulator, Tim-3, on CD4⁺ T cells, but this observation was not limited to HCV-reactive T cells (179). HCV-specific CD4⁺ T cells express the inhibitory co-receptor programmed death-1 (PD-1) (180, 181) during acute and chronic

infection. It has been reported that blockade of PD-1, TGF β and IL-10 (181) or IL-2 supplementation (173) may partially restore functionality of HCV-specific CD4⁺ T cells. Regulatory T cells may play a role in HCV persistence; in a cohort of injection drug users with acute HCV infection, increased regulatory T cell function and decreased Th17 function correlated with progression to chronicity (182). Importantly, it is not clear whether these changes are causes or effects of CD4⁺ T cell failure in persisting HCV infection. Eliminating HCV-specific CD4⁺ T cells might benefit the host by minimizing inflammation and tissue destruction (175). Epitope escape appears to play a limited role in the failure of CD4⁺ T cell responses (183, 184); this contrasts with the prominent role of epitope escape in the failure of CD8⁺ T cell responses, discussed below.

6.3. CD8⁺ T cell failure

HCV-specific CD8⁺ T cell responses fail due to T cell exhaustion and epitope escape. CD8⁺ T cell exhaustion occurs through a multi-step process in which antigen-specific cells progressively lose effector functions and reduce their expression of cytokine receptors needed for memory CD8⁺ T cell homeostatic proliferation (158). Exhaustion may be protective in persistent infections because it reduces the risk that immune responses themselves will cause pathology (158). Exhausted, HCV antigen-specific CD8⁺ T cells can be observed in the blood and liver as acute infection progresses to chronicity (185–188). Features of these cells include expression of two or more inhibitory co-receptors (such as PD-1, 2B4, Tim-3, CTLA4, KLRG1, or CD160), and reduced expression of the IL-7 receptor α chain, CD127. IL-7, one of the common- γ chain receptor cytokine family members, supports memory CD8⁺ T cell survival, function, homeostatic and antigen-dependent proliferation (158, 189, 190). Other members of this cytokine family, IL-7, IL-15, and IL-21, also play key roles in T cell survival and function. Down-regulation of CD127 makes CD8⁺ T cells less responsive to IL-7. Extensive CD127 down-regulation during the acute phase predicts HCV persistence in experimentally infected chimpanzees (191). Of note, however, transient loss of CD127 also identifies effector T cells (192). As acute HCV infection progresses toward persistence, HCV-specific CD8⁺ T cells lose CD127 expression, gain PD-1 expression, and undergo caspase 9-mediated “death by neglect” due to loss of cytokine survival signals (193). In contrast, protective HCV-specific CD8⁺ T cells elicited by an experimental HCV vaccine expressed CD127 (194). Exhausted CD8⁺ T cells may be rescued *in vitro* with IL-2, IL-7 and IL-15 supplementation (193). IL-21 production by CD4⁺ T cells is associated with resolution of acute HCV infection (182).

The association of exhausted HCV-specific T cells with chronic HCV infection raises the possibility of therapeutic efforts to reverse T cell exhaustion during chronic infection (171). Blockade of PD-1 during persistent LCMV infection in mice can restore immune-mediated control; however, PD-1 signaling also protects the body from immune-mediated pathology (195–197). Also important, intrahepatic T cells typically express at least some inhibitory receptors even in the absence of viral infection (188), and HCV-specific T cells continue to express PD-1 even after spontaneous clearance of infection (198). PD-1 blockade may not be sufficient to reverse T cell exhaustion (199) or restore immune control of HCV in an established persistent infection (200). Blockade of other inhibitory co-receptors, such as Tim-3 (179, 182), CTLA-4 (201), and/or 2B4 (188) might also hold some

immunotherapeutic promise. The success of any therapeutic strategy aimed at blockade of inhibitory co-receptors would, of course, be contingent on the presence and survival of some critical number of antigen-specific T cells.

6.4. Immune escape and T cell responses

Another pathway to the failure of HCV-specific T cells is immunological escape. HCV's error-prone replication mechanism produces amino acid changes in viral proteins at a dizzying rate (202). The resulting pool of novel viral RNA sequences provides the raw material for natural selection and rapid evolution under pressures that include immune recognition. HCV must evolve within each new host to maximize its potential to replicate and minimize immune-mediated clearance (203–209). As HCV infects a new host, viral sequence diversity may initially be limited by a founder effect. Those viral sequences capable of robust replication in the new environment have a selective advantage; sequence changes conferring efficient viral spread and replication sometimes restore consensus polypeptide sequences for a given HCV genotype (210). This may also represent a release of immunological pressure from the previous (donor) host. HCV may replicate for several weeks before the acutely infected host mounts an adaptive immune response. The onset of HCV-specific T cell responses is associated with signs of hepatocyte damage and a decline in viral load, suggesting that initial T cell responses mediate selection for viral sequence changes that abolish T cell recognition (211, 212), just as antibodies mediate selection for viral sequences that abolish antibody recognition (213, 214). The impact of T cell-mediated selection is seen in the selection of specific mutations in individuals expressing different HLA alleles (50, 167, 204, 215–220). For unknown reasons, selection mediated by HLA-B alleles may be stronger than that mediated by HLA-A alleles (167). Viral immune escape may be more successful in individuals mounting a less diverse T cell response (221, 222). Sequence changes are not unlimited, however, and viral immune escape is constrained by the need to retain replicative fitness (207, 208, 223). Some viral sequence changes that could mediate immunological escape are not tolerated because they reduce viral replicative fitness; T cell responses targeting these epitopes may be blunted by exhaustion and deletion (224, 225), as discussed in the previous paragraph. Once chronic infection is established, the selective pressure for continued T cell epitope escape is apparently lost (226–228). Reductions in immune pressure, for example during pregnancy, may be associated with reversion of escape mutations (223). Conversely, some exhausted T cells may be released from their exhausted state by loss of the epitope they target: viral sequence mutations that eliminate recognition by an exhausted T cell clone are associated with functional recovery of those T cells (229).

7. The humoral immune response

Antibody (**Ab**) responses are observed in chronic HCV infection, but their roles in control of HCV remain controversial (230, 231). As observed for T cell responses, Ab responses are delayed during acute HCV infection compared to other viral infections (232, 233) (Figure 4). Clearance of acute HCV infection can occur in the absence of a detectable HCV-stimulated Ab response (166, 234–239), and Abs to HCV can wane or vanish after spontaneous or treatment-induced resolution of infection (33, 170, 240, 241). Ab responses

target both structural and non-structural proteins. However, all known virus-neutralizing Ab (**nAb**) target the envelope glycoproteins E1 and, especially, E2. It is not clear whether Abs against non-structural proteins can recognize intact infected cells or affect HCV replication in infected cells; these Abs might contribute to clearance and opsonization of debris from infected tissue.

Lacking robust in vitro systems to study primary HCV isolates, researchers have turned to artificial in vitro systems to address questions of Ab-mediated neutralization of HCV infection (reviewed in (242)). Many recent studies have utilized lentiviral particles pseudotyped with HCV E1E2 heterodimers (**HCVpp**). HCVpp deliver reporter genes to hepatoma cell lines that express the HCV entry factors, SR-BI, CD81, Claudin-1 and Occludin (43, 242). Other studies have used chimeric cell-culture-derived HCV (**HCVcc**), substituting the core-NS2 regions (Figure 1) from HCV isolates of interest into the laboratory workhorse JFH-1 isolate (reviewed in (242)). Sera from patients with persistent HCV infection typically contain high-titer Abs able to neutralize infection by HCVpp bearing E1E2 from at least some genotypes (231, 237, 243, 244). Of interest, nAbs that block infection by HCVpp may be poorly effective against HCVcc (245).

Numerous studies support a role for nAbs in vivo. In chimpanzees, the closest animal model for human infection, early treatment with nAbs could prevent infection, and nAb infusion reduced viral load in persistent infection (246, 247). In immunodeficient mice with chimeric human livers, HCV infection can be prevented by nAb treatment before infection (248, 249), and persistent infection can be treated with nAb to induce an apparent cure (250). Similarly, HCV can infect the liver in mice expressing human CD81 and Occludin, and in these mice, too, broadly neutralizing monoclonal Abs can provide protection if administered before infection (251, 252) and even after establishment of infection (250). Importantly, the mouse models of HCV persistence used in these studies are, by necessity, immunodeficient, highlighting the important role played by nAb.

Humans, too, benefit from HCV-specific nAbs. Acutely infected patients destined to clear infection without treatment may develop an early, broadly crossreactive (effective against multiple HCV genotypes) nAb response, while early nAb responses are weaker and less broadly crossreactive in patients who progress to chronic infection (33, 170, 241, 253–255). A rare incidence of spontaneous clearance of chronic infection was reported to follow development of a broadly-reactive nAb response (170). Many broadly crossreactive nAbs target a restricted set of epitopes within E2, and are believed to block viral binding to entry factors (reviewed in (230, 231)). Broadly crossreactive nAbs may limit viral escape options, much as a broadly directed T cell response does, by targeting highly conserved epitopes. However, a discouraging report recently showed that nAb binding to highly conserved neutralizing epitopes is vulnerable to amino acid changes in E2 at sites outside of the nAb epitope (214). Some amino acid changes of this type may have a negative impact on viral infectivity (256). nAb may reduce viral loads sufficiently to release T cells from exhaustion caused by excessive antigenic stimulation (170). nAb can provide passive protection against infection and, indeed, nAb activity in bulk human immunoglobulin preparations protected recipients from HCV infection before the advent of HCV serological screening (249, 257–259). Most serum nAb activity in persistently infected individuals rests in an IgG fraction

(237). The loss of CD4+ T cells in HIV co-infection reduces HCV-specific nAb breadth and titers (260).

7.1. Escape from nAb

HCV is thought to escape from sterilizing humoral immunity by rapid sequence variation, by stimulating the production of interfering antibodies, masking neutralization epitopes, and likely by concealing itself within lipoviral particles (reviewed in (230, 231)). Competition between nAb and interfering non-neutralizing Ab may disrupt nAb function: the CD81-binding loop region of E2 is targeted by both neutralizing and non-neutralizing Abs, with some reports suggesting that the non-neutralizing Abs may limit nAb access to key neutralization epitopes (261–264). This hypothesis is not universally accepted (231, 263–268). Neutralization epitopes may be masked by extensive glycosylation (see below) (269). HCV is assembled into lipoviral particles (42), and ultrastructural studies of HCVcc showed greater surface exposure of host apolipoprotein E than of viral E2 (270). While it is thought that lipoviral particle association may protect HCV from nAb, it is difficult to test this hypothesis quantitatively. Some HCV spread occurs between adjacent cells in a fashion that is resistant to E2-specific nAb (46, 47, 271–275). This type of spread may remain sensitive to smaller Ab-like reagents including an alpaca nanobody (276). Despite the multitude of potential escape mechanism, a recent report showed nAb-dependent cure of persistent HCV infection in immunodeficient mice bearing human liver grafts (250).

Structural and functional studies of E2 have revealed that key neutralization epitopes may be concealed behind a decoy structure—the so called first hypervariable (**HVR1**) sequence near the amino terminus of E2 (259, 277, 278). This sequence is highly immunogenic but elicits weakly cross-reactive, isolate-specific Abs. The HVR1 sequence is under few functional constraints, and indeed E2 lacking HVR1 is functional (278). HCV readily tolerates amino acid changes that abolish recognition by HVR1-specific Abs. Several reports link E2 sequence evolution to nAb escape during chronic infection (213, 254, 279, 280). Host nAb responses lag behind the shape-shifting E2 (213, 254). That nAbs fail to neutralise the dominant viral strain at a given time, yet successfully neutralise previously dominant viral strains in the same patient, demonstrates the continued evolution and escape of the virus under selective pressure from nAbs, with the humoral immune system always, sadly, one step behind (213). Whereas nAb responses select E1E2 sequence variation over time, envelope sequence changes are not observed in hypogammaglobulinemic patients (281–283). nAb with broad, multi-isolate reactivity bind to highly conserved and functionally constrained sequences involved in entry factor binding. These epitopes are protected by the HVR (259, 277, 278, 284) and, as discussed in the next paragraph, by glycosylation.

The ectodomains of HCV's E1 and E2 envelope glycoproteins are heavily glycosylated: glycans contribute almost half of the ectodomains' apparent molecular weight. E2, which is more immunogenic than E1, contains nine N-linked glycosylation sites conserved across all HCV genotypes (two additional sites are conserved in most isolates). Glycans play essential roles in assembly and folding of the E1E2 heterodimer, and are required for viral entry (269, 285–287). The glycans limit nAb access to E1E2, protecting virus from neutralization (269). Structural analysis of E2-nAb complexes showed that heavy glycosylation can mask

neutralization epitopes (284). Removal of the glycan shield increases HCVpp sensitivity to nAb (288).

7.2 An immune response gone wrong? Mixed cryoglobulinemia

Hepatocytes are the primary target of HCV infection, but as discussed elsewhere in this book, B lymphocyte dysfunction and malignancy lead to extrahepatic disease in many chronic HCV patients (289, 290). Mixed cryoglobulinemia (MC) is a common extrahepatic manifestation (reviewed in (291, 292)). In MC, the intravascular deposition of immune complexes, containing IgM rheumatoid factor, polyclonal IgG, and viral RNA, elicits an inflammatory reaction that can lead to vasculitis, nephropathy, and neuropathy (291, 292); this apparently benign lymphoproliferative condition may progress to B cell non-Hodgkin lymphoma (293). Successful antiviral therapy may result in complete regression of HCV-associated lymphoma (293). B cells expressing rheumatoid factor-like IgM are clonally expanded in HCV patients with symptomatic MC, supporting the hypothesis that MC arises through antigen-driven stimulation of specific B cell clones (294, 295). Notably, many reports indicate that clonally-expanded B cells in HCV-associated MC, as well as HCV-associated non-Hodgkin lymphomas, express a stereotypical antigen receptor encoded by rearranged VH1-69 (also called VH51p1) and V κ 3-20 (also known as kv325 and A27) variable region genes (294, 296–301).

Other mechanisms have been proposed for the development of HCV-associated MC and non-Hodgkin lymphoma, but these mechanisms are not supported by our current understanding of HCV tropism, structure, and replication (reviewed in (233)). Models proposing that HCV's E2 envelope protein induces polyclonal B cell activation by crosslinking CD81 on B cells (302) are inconsistent with clinical observations, in that B cell activation in MC is clonally restricted rather than polyclonal (294, 296–301). Furthermore, it has not been demonstrated that intact circulating lipoviral particles (42) can mediate the activation reported in vitro with high concentrations of recombinant E2. While it has been suggested that HCV may infect B cells (303), and thereby cause mutations or functional changes, B cells do not express the array of entry factors (including two tight junction proteins, Claudin-1 and Occludin) needed for HCV infection of hepatocytes (42, 44, 233). Neither cell culture-derived HCV of genotype 2a, nor HCV pseudoparticles bearing envelope glycoproteins of various genotypes, can infect primary B cells or B cell lines (44, 304). Levels of HCV RNA associated with patient lymphocytes are far below one copy per cell (140, 305–307), suggesting that replication, if any, is inefficient in human lymphocytes. Observations of similar clonally expanded B cells in multiple MC patients, in different studies from different researchers, strongly suggest that a common antigenic stimulus plays a role in development of MC. Work is ongoing to probe the roles of viral and self antigens in driving typical MC-related clonal expansion (308); host genetic factors (309) and changes in cytokine levels (310) may also contribute.

8. Outlook

As we move into an era in which diagnosed HCV infections can be treated effectively (although not economically), a prophylactic vaccine remains a critical unmet need (21, 22,

311, 312). Therapeutic vaccines and immune enhancement strategies may also contribute to future treatment regimes. Understanding the mechanisms of immune control and failure will be essential to the development of effective vaccines. Significant progress has been made (22). Roles for both humoral and cell-mediated immunity must be considered. A prophylactic vaccine stimulating a robust, broadly-directed (30, 313), cross-reactive (multiple genotypes) (314), and polyfunctional (194, 313) T cell response is desirable if the goal is to prevent persistent HCV infection. This will be challenging because, even in subjects who have achieved spontaneous resolution of HCV infection, immunity may be largely strain or genotype-specific. Viral epitopes that can stimulate a universally protective anti-HCV immune response have not yet been identified. A prophylactic vaccine that stimulates production of broadly reactive nAb is appealing because of its potential to block even acute HCV infection. Emerging evidence indicates that broadly crossreactive nAb can treat established infection (250), underscoring the need for inclusion of the structural proteins, E1 and E2, in vaccine candidates.

Acknowledgments

Funded by the National Institutes of Health (R01AI060561, R01AI089957).

Bibliography

1. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. *Nat Rev Gastroenterol Hepatol*. 2013; 10(9):553–562. [PubMed: 23817321]
2. Lavanchy D. Evolving epidemiology of hepatitis C virus. *Clin Microbiol Infect*. 2011; 17(2):107–115. [PubMed: 21091831]
3. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. *Hepatology*. 2013; 57(4): 1333–1342. [PubMed: 23172780]
4. Seeff LB. The history of the “natural history” of hepatitis C (1968–2009). *Liver Int*. 2009; 29(Suppl 1):89–99.
5. Webster DP, Klennerman P, Dusheiko GM. Hepatitis C. *Lancet*. 2015; 385(9973):1124–1135. [PubMed: 25687730]
6. Joshi D, Pinzani M, Carey I, Agarwal K. Recurrent HCV after liver transplantation-mechanisms, assessment and therapy. *Nat Rev Gastroenterol Hepatol*. 2014; 11(12):710–721. [PubMed: 25023032]
7. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. *Ann Intern Med*. 2012; 156(4): 271–278. [PubMed: 22351712]
8. Ly KN, Xing J, Klevens RM, Jiles RB, Holmberg SD. Causes of death and characteristics of decedents with viral hepatitis, United States, 2010. *Clin Infect Dis*. 2014; 58(1):40–49. [PubMed: 24065331]
9. Chen JY, Feeney ER, Chung RT. HCV and HIV co-infection: mechanisms and management. *Nat Rev Gastroenterol Hepatol*. 2014; 11(6):362–371. [PubMed: 24535328]
10. Thomas DL, Leoutsakas D, Zabransky T, Kumar MS. Hepatitis C in HIV-infected individuals: cure and control, right now. *Journal of the International AIDS Society*. 2011; 14:22. [PubMed: 21548988]
11. Sagnelli E, Pisaturo M, Martini S, Sagnelli C, Filippini P, Coppola N. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection. *Expert opinion on pharmacotherapy*. 2014; 15(10): 1337–1349. [PubMed: 24773464]

12. Kamal S, Madwar M, Bianchi L, Tawil AE, Fawzy R, Peters T, et al. Clinical, virological and histopathological features: long-term follow-up in patients with chronic hepatitis C co-infected with *S. mansoni*. *Liver*. 2000; 20(4):281–289. [PubMed: 10959806]
13. Tse MT. All-oral HCV therapies near approval. *Nature reviews Drug Discovery*. 2013; 12(6):409–411.
14. Lange CM, Jacobson IM, Rice CM, Zeuzem S. Emerging therapies for the treatment of hepatitis C. *EMBO Mol Med*. 2014; 6(1):4–15. [PubMed: 24106239]
15. Gogela NA, Lin MV, Wisocky JL, Chung RT. Enhancing our understanding of current therapies for hepatitis C virus (HCV). *Curr HIV/AIDS Rep*. 2015; 12(1):68–78. [PubMed: 25761432]
16. Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. *Nat Med*. 2013; 19(7):837–849. [PubMed: 23836234]
17. Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. *Hepatology*. 2009; 50(6):1750–1755. [PubMed: 19824079]
18. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. *Nat Med*. 2013; 19(7):850–858. [PubMed: 23836235]
19. Dore GJ, Feld JJ. Hepatitis C virus therapeutic development: in pursuit of “perfectovir”. *Clin Infect Dis*. 2015; 60(12):1829–1836. [PubMed: 25761867]
20. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. *Dig Liver Dis*. 2011; 43(1):66–72. [PubMed: 20739252]
21. Liang TJ. Current progress in development of hepatitis C virus vaccines. *Nat Med*. 2013; 19(7):869–878. [PubMed: 23836237]
22. Swadling L, Klennerman P, Barnes E. Ever closer to a prophylactic vaccine for HCV. *Expert Opin Biol Ther*. 2013; 13(8):1109–1124. [PubMed: 23651228]
23. Baumert TF, Fauvelle C, Chen DY, Lauer GM. A prophylactic hepatitis C virus vaccine: a distant peak still worth climbing. *J Hepatol*. 2014; 61(1 Suppl):S34–S44. [PubMed: 25443345]
24. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. *Journal of viral hepatitis*. 2006; 13(1):34–41. [PubMed: 16364080]
25. Grebely J, Page K, Sacks-Davis R, van der Loeff MS, Rice TM, Bruneau J, et al. The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. *Hepatology*. 2014; 59(1):109–120. [PubMed: 23908124]
26. Page K, Hahn JA, Evans J, Shiboski S, Lum P, Delwart E, et al. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. *The Journal of infectious diseases*. 2009; 200(8):1216–1226. [PubMed: 19764883]
27. Page K, Osburn W, Evans J, Hahn JA, Lum P, Asher A, et al. Frequent longitudinal sampling of hepatitis C virus infection in injection drug users reveals intermittently detectable viremia and reinfection. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2013; 56(3):405–413. [PubMed: 23090930]
28. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. *Nature*. 2009; 461(7265):798–801. [PubMed: 19759533]
29. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource. *Hepatology*. 2014; 59(1):318–327. [PubMed: 24115039]
30. von Delft A, Humphreys IS, Brown A, Pfafferoth K, Lucas M, Klennerman P, et al. The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design. *Gut*. 2015
31. Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, et al. Protection against persistence of hepatitis C. *Lancet*. 2002; 359(9316):1478–1483. [PubMed: 11988247]
32. Aitken CK, Lewis J, Tracy SL, Spelman T, Bowden DS, Bharadwaj M, et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. *Hepatology*. 2008; 48(6):1746–1752. [PubMed: 18844233]

33. Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L, Ray SC, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. *Gastroenterology*. 2010; 138(1):315–324. [PubMed: 19782080]
34. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. *Nature reviews*. 2007; 5(6):453–463.
35. Bartenschlager R, Lohmann V, Penin F. The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. *Nature reviews*. 2013; 11(7):482–496.
36. Paul D, Madan V, Bartenschlager R. Hepatitis C virus RNA replication and assembly: living on the fat of the land. *Cell Host Microbe*. 2014; 16(5):569–579. [PubMed: 25525790]
37. Bartenschlager R, Penin F, Lohmann V, Andre P. Assembly of infectious hepatitis C virus particles. *Trends Microbiol*. 2011; 19(2):95–103. [PubMed: 21146993]
38. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. *Science*. 2005; 309(5740):1577–1581. [PubMed: 16141076]
39. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, et al. Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection. *Science*. 2010; 327:198. [PubMed: 19965718]
40. Luna JM, Scheel TK, Danino T, Shaw KS, Mele A, Fak JJ, et al. Hepatitis C Virus RNA Functionally Sequesters miR-122. *Cell*. 2015; 160(6):1099–1110. [PubMed: 25768906]
41. Shimizu Y, Hishiki T, Ujino S, Sugiyama K, Funami K, Shimotohno K. Lipoprotein component associated with hepatitis C virus is essential for virus infectivity. *Curr Opin Virol*. 2011; 1(1):19–26. [PubMed: 22440563]
42. Lindenbach BD, Rice CM. The ins and outs of hepatitis C virus entry and assembly. *Nature reviews*. 2013; 11(10):688–700.
43. Douam F, Lavillette D, Cosset FL. The mechanism of HCV entry into host cells. *Prog Mol Biol Transl Sci*. 2015; 129:63–107. [PubMed: 25595801]
44. Marukian S, Jones CT, Andrus L, Evans MJ, Ritola KD, Charles ED, et al. Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. *Hepatology*. 2008; 48:1843–1850. [PubMed: 19003912]
45. Graw F, Balagopal A, Kandathil AJ, Ray SC, Thomas DL, Ribeiro RM, et al. Inferring viral dynamics in chronically HCV infected patients from the spatial distribution of infected hepatocytes. *PLoS Comput Biol*. 2014; 10(11):e1003934. [PubMed: 25393308]
46. Wieland S, Makowska Z, Campana B, Calabrese D, Dill MT, Chung J, et al. Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver. *Hepatology*. 2014; 59(6):2121–2130. [PubMed: 24122862]
47. Kandathil AJ, Graw F, Quinn J, Hwang HS, Torbenson M, Perelson AS, et al. Use of laser capture microdissection to map hepatitis C virus-positive hepatocytes in human liver. *Gastroenterology*. 2013; 145(6):1404–1413. e10. [PubMed: 23973767]
48. Horner SM, Gale M Jr. Regulation of hepatic innate immunity by hepatitis C virus. *Nat Med*. 2013; 19(7):879–888. [PubMed: 23836238]
49. Li K, Lemon SM. Innate immune responses in hepatitis C virus infection. *Seminars in immunopathology*. 2013; 35(1):53–72. [PubMed: 22868377]
50. Dustin LB, Rice CM. Flying under the radar: The immunobiology of hepatitis C. *Annu Rev Immunol*. 2007; 25:71–99. [PubMed: 17067278]
51. Horner SM, Gale M Jr. Intracellular innate immune cascades and interferon defenses that control hepatitis C virus. *J Interferon Cytokine Res*. 2009; 29(9):489–498. [PubMed: 19708811]
52. Ireton RC, Gale M Jr. Pushing to a cure by harnessing innate immunity against hepatitis C virus. *Antiviral Res*. 2014; 108:156–164. [PubMed: 24907428]
53. Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale M Jr. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. *Nature*. 2008; 454(7203):523–527. [PubMed: 18548002]
54. Schnell G, Loo YM, Marcotrigiano J, Gale M Jr. Uridine composition of the poly-U/UC tract of HCV RNA defines non-self recognition by RIG-I. *PLoS Pathog*. 2012; 8(8):e1002839. [PubMed: 22912574]

55. Dixit E, Kagan JC. Intracellular pathogen detection by RIG-I-like receptors. *Adv Immunol.* 2013; 117:99–125. [PubMed: 23611287]
56. Uzri D, Gehrke L. Nucleotide sequences and modifications that determine RIG-I/RNA binding and signaling activities. *J Virol.* 2009; 83(9):4174–4184. [PubMed: 19224987]
57. Gack MU, Shin YC, Joo CH, Urano T, Liang C, Sun L, et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. *Nature.* 2007; 446(7138):916–920. [PubMed: 17392790]
58. Liu S, Chen J, Cai X, Wu J, Chen X, Wu Y-T, et al. MAVS recruits multiple ubiquitin E3 ligases to activate antiviral signaling cascades. *eLife.* 2013;2.
59. Zinngrebe J, Montinaro A, Peltzer N, Walczak H. Ubiquitin in the immune system. *EMBO Rep.* 2014; 15(1):28–45. [PubMed: 24375678]
60. Odendall C, Dixit E, Stavru F, Bierne H, Franz KM, Durbin AF, et al. Diverse intracellular pathogens activate type III interferon expression from peroxisomes. *Nat Immunol.* 2014; 15(8): 717–726. [PubMed: 24952503]
61. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. *Nature.* 2005; 437(7062):1167–1172. [PubMed: 16177806]
62. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. *Proc Natl Acad Sci U S A.* 2005; 102(49):17717–17722. [PubMed: 16301520]
63. Bellecave P, Sarasin-Filipowicz M, Donze O, Kennel A, Gouttenoire J, Meylan E, et al. Cleavage of mitochondrial antiviral signaling protein in the liver of patients with chronic hepatitis C correlates with a reduced activation of the endogenous interferon system. *Hepatology.* 2010; 51(4): 1127–1136. [PubMed: 20044805]
64. Loo YM, Owen DM, Li K, Erickson AK, Johnson CL, Fish PM, et al. Viral and therapeutic control of IFN- β promoter stimulator 1 during hepatitis C virus infection. *Proc Natl Acad Sci U S A.* 2006; 103(15):6001–6006. [PubMed: 16585524]
65. Weber M, Gawanbacht A, Habjan M, Rang A, Borner C, Schmidt Anna M, et al. Incoming RNA Virus Nucleocapsids Containing a 5'-Triphosphorylated Genome Activate RIG-I and Antiviral Signaling. *Cell Host & Microbe.* 2013; 13(3):336–346. [PubMed: 23498958]
66. Shimoike T, McKenna SA, Lindhout DA, Puglisi JD. Translational insensitivity to potent activation of PKR by HCV IRES RNA. *Antiviral Res.* 2009; 83(3):228–237. [PubMed: 19467267]
67. Arnaud N, Dabo S, Akazawa D, Fukasawa M, Shinkai-Ouchi F, Hugon J, et al. Hepatitis C virus reveals a novel early control in acute immune response. *PLoS Pathog.* 2011; 7(10):e1002289. [PubMed: 22022264]
68. Garaigorta U, Chisari FV. Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation. *Cell Host Microbe.* 2009; 6(6):513–522. [PubMed: 20006840]
69. Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. *Gastroenterology.* 2005; 128(5):1437–1444. [PubMed: 15887125]
70. Chen L, Sun J, Meng L, Heathcote J, Edwards AM, McGilvray ID. ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment. *J Gen Virol.* 2010; 91(Pt 2):382–388. [PubMed: 19846672]
71. Dustin LB, Cashman SB, Laidlaw SM. Immune control and failure in HCV infection--tipping the balance. *J Leukoc Biol.* 2014; 96(4):535–548. [PubMed: 25015956]
72. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. *Proc Natl Acad Sci U S A.* 2005; 102(8):2992–2997. [PubMed: 15710891]
73. Bigger CB, Brasky KM, Lanford RE. DNA microarray analysis of chimpanzee liver during acute resolving hepatitis C virus infection. *J Virol.* 2001; 75(15):7059–7066. [PubMed: 11435586]
74. Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C, et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. *Proc Natl Acad Sci U S A.* 2002; 99(24):15661–15668. [PubMed: 12441397]

75. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, et al. Genomic analysis of the host response to hepatitis C virus infection. *Proc Natl Acad Sci U S A*. 2002; 99(24):15669–15674. [PubMed: 12441396]
76. Schoggins JW, Rice CM. Innate immune responses to hepatitis C virus. *Curr Top Microbiol Immunol*. 2013; 369:219–242. [PubMed: 23463203]
77. Marukian S, Andrus L, Sheahan TP, Jones CT, Charles ED, Ploss A, et al. Hepatitis C virus induces interferon-lambda and interferon-stimulated genes in primary liver cultures. *Hepatology*. 2011; 54(6):1913–1923. [PubMed: 21800339]
78. Park H, Serti E, Eke O, Muchmore B, Prokunina-Olsson L, Capone S, et al. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. *Hepatology*. 2012; 56(6):2060–2070. [PubMed: 22706965]
79. Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Nouredin M, et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. *Gastroenterology*. 2012; 142(4):978–988. [PubMed: 22248663]
80. Sheahan T, Imanaka N, Marukian S, Dörner M, Liu P, Ploss A, et al. Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. *Cell Host & Microbe*. 2014; 15(2):190–202. [PubMed: 24528865]
81. Andrus L, Marukian S, Jones CT, Catanese MT, Sheahan TP, Schoggins JW, et al. Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells. *Hepatology*. 2011; 54(6):1901–1912. [PubMed: 22144107]
82. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huin C, et al. Genetic variation in *IL28B* and spontaneous clearance of hepatitis C virus. *Nature*. 2009; 461:798–802. [PubMed: 19759533]
83. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in *IL28B* is associated with chronic hepatitis C and treatment failure: a genome-wide association study. *Gastroenterology*. 2010; 138(4):1338–1345. 45, e1–e7. [PubMed: 20060832]
84. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in *IL28B* predicts hepatitis C treatment-induced viral clearance. *Nature*. 2009; 461(7262):399–401. [PubMed: 19684573]
85. Tanaka Y, Nishida Y, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of *IL28B* with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. *Nat Genet*. 2009; 41(10):1105–1109. [PubMed: 19749757]
86. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. *IL28B* is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. *Nat Genet*. 2009; 41(10):1100–1104. [PubMed: 19749758]
87. Laidlaw SM, Dustin LB. Interferon lambda: opportunities, risks, and uncertainties in the fight against HCV. *Frontiers in immunology*. 2014; 5:545. [PubMed: 25400636]
88. O’Brien TR, Prokunina-Olsson L, Donnelly RP. IFN-lambda4: the paradoxical new member of the interferon lambda family. *J Interferon Cytokine Res*. 2014; 34(11):829–838. [PubMed: 24786669]
89. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. *Gastroenterology*. 2010; 139(2):499–509. [PubMed: 20434452]
90. Shebl FM, Maeder D, Shao Y, Prokunina-Olsson L, Schadt EE, O’Brien TR. In the absence of HCV infection, interferon stimulated gene expression in liver is not associated with *IL28B* genotype. *Gastroenterology*. 2010; 139(4):1422–1424. [PubMed: 20800110]
91. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, et al. Interferon signaling and treatment outcome in chronic hepatitis C. *Proc Natl Acad Sci U S A*. 2008; 105(19):7034–7039. [PubMed: 18467494]
92. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, et al. *IL28B* genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. *Hepatology*. 2010; 52(6):1888–1896. [PubMed: 20931559]
93. Charles ED, Dustin LB. Chemokine antagonism in chronic hepatitis C virus infection. *J Clin Invest*. 2011; 121(1):25–27. [PubMed: 21183783]

94. Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semmo N, et al. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. *J Exp Med*. 2013; 210(6):1109–1116. [PubMed: 23712427]
95. McFarland AP, Horner SM, Jarret A, Joslyn RC, Bindewald E, Shapiro BA, et al. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. *Nat Immunol*. 2013
96. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. *Nat Genet*. 2013; 45(2):164–171. [PubMed: 23291588]
97. Aka PV, Kuniholm MH, Pfeiffer RM, Wang AS, Tang W, Chen S, et al. Association of the IFNL4-DeltaG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus. *J Infect Dis*. 2014; 209(3):350–354. [PubMed: 23956438]
98. Terczynska-Dyla E, Bibert S, Duong FH, Krol I, Jorgensen S, Collinet E, et al. Reduced IFNlambda4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. *Nat Commun*. 2014; 5:5699. [PubMed: 25534433]
99. Hamming OJ, Terczynska-Dyla E, Vieyres G, Dijkman R, Jorgensen SE, Akhtar H, et al. Interferon lambda 4 signals via the IFNlambda receptor to regulate antiviral activity against HCV and coronaviruses. *EMBO J*. 2013; 32(23):3055–3065. [PubMed: 24169568]
100. Takahashi K, Asabe S, Wieland S, Garaigorta U, Gastaminza P, Isogawa M, et al. Plasmacytoid dendritic cells sense hepatitis C virus-infected cells, produce interferon, and inhibit infection. *Proc Natl Acad Sci U S A*. 2010; 107(16):7431–7436. [PubMed: 20231459]
101. Dreux M, Garaigorta U, Boyd B, Decembre E, Chung J, Whitten-Bauer C, et al. Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity. *Cell Host Microbe*. 2012; 12(4):558–570. [PubMed: 23084922]
102. Grabski E, Wappler I, Pfaender S, Steinmann E, Haid S, Dzionek A, et al. Efficient virus assembly, but not infectivity, determines the magnitude of hepatitis C virus-induced interferon alpha responses of plasmacytoid dendritic cells. *J Virol*. 2015; 89(6):3200–3208. [PubMed: 25552725]
103. Stone AE, Giugliano S, Schnell G, Cheng L, Leahy KF, Golden-Mason L, et al. Hepatitis C virus pathogen associated molecular pattern (PAMP) triggers production of lambda-interferons by human plasmacytoid dendritic cells. *PLoS Pathog*. 2013; 9(4):e1003316. [PubMed: 23637605]
104. Zhang S, Kodys K, Li K, Szabo G. Human type 2 myeloid dendritic cells produce interferon-lambda and amplify interferon-alpha in response to hepatitis C virus infection. *Gastroenterology*. 2013; 144(2):414–425. e7. [PubMed: 23089201]
105. Kelly A, Fahey R, Fletcher JM, Keogh C, Carroll AG, Siddachari R, et al. CD141(+) myeloid dendritic cells are enriched in healthy human liver. *J Hepatol*. 2014; 60(1):135–142. [PubMed: 23968887]
106. Yoshio S, Kanto T, Kuroda S, Matsubara T, Higashitani K, Kakita N, et al. Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-lambda in response to hepatitis C virus. *Hepatology*. 2013; 57(5):1705–1715. [PubMed: 23213063]
107. Giugliano S, Kriss M, Golden-Mason L, Dobrinskikh E, Stone AE, Soto-Gutierrez A, et al. Hepatitis C virus infection induces autocrine interferon signaling by human liver endothelial cells and release of exosomes, which inhibits viral replication. *Gastroenterology*. 2015; 148(2):392–402. e13. [PubMed: 25447848]
108. Schoggins JW, Rice CM. Interferon-stimulated genes and their antiviral effector functions. *Curr Opin Virol*. 2011; 1(6):519–525. [PubMed: 22328912]
109. Metz P, Reuter A, Bender S, Bartenschlager R. Interferon-stimulated genes and their role in controlling hepatitis C virus. *J Hepatol*. 2013; 59(6):1331–1341. [PubMed: 23933585]
110. Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. *Annu Rev Immunol*. 2014; 32:513–545. [PubMed: 24555472]
111. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. *Gastroenterology*. 2006; 131(6):1887–1898. [PubMed: 17087946]

112. Jilg N, Lin W, Hong J, Schaefer EA, Wolski D, Meixong J, et al. Kinetic differences in the induction of interferon stimulated genes by interferon-alpha and interleukin 28B are altered by infection with hepatitis C virus. *Hepatology*. 2014; 59(4):1250–1261. [PubMed: 23913866]
113. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. *Nature*. 2011; 472(7344): 481–485. [PubMed: 21478870]
114. Helbig KJ, Eyre NS, Yip E, Narayana S, Li K, Fiches G, et al. The antiviral protein viperin inhibits hepatitis C virus replication via interaction with nonstructural protein 5A. *Hepatology*. 2011; 54(5):1506–1517. [PubMed: 22045669]
115. Bauhofer O, Ruggieri A, Schmid B, Schirmacher P, Bartenschlager R. Persistence of HCV in quiescent hepatic cells under conditions of an interferon-induced antiviral response. *Gastroenterology*. 2012; 143(2):429–438. e8. [PubMed: 22522091]
116. Rand U, Rinas M, Schwerk J, Nohren G, Linnes M, Kroger A, et al. Multi-layered stochasticity and paracrine signal propagation shape the type-I interferon response. *Mol Syst Biol*. 2012; 8:584. [PubMed: 22617958]
117. Saha B, Szabo G. Innate immune cell networking in hepatitis C virus infection. *J Leukoc Biol*. 2014; 96(5):757–766. [PubMed: 25001860]
118. Racanelli V, Rehermann B. The liver as an immunological organ. *Hepatology*. 2006; 43(2 Suppl 1):S54–S62. [PubMed: 16447271]
119. Cheent K, Khakoo SI. Natural killer cells and hepatitis C: action and reaction. *Gut*. 2011; 60(2): 268–278. [PubMed: 20876777]
120. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. *Annu Rev Immunol*. 2013; 31:227–258. [PubMed: 23516982]
121. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. *Science*. 2011; 331(6013):44–49. [PubMed: 21212348]
122. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. *Science*. 2004; 305(5685):872–874. [PubMed: 15297676]
123. Knapp S, Warshaw U, Hegazy D, Brackenbury L, Guha IN, Fowell A, et al. Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. *Hepatology*. 2010; 51(4):1168–1175. [PubMed: 20077564]
124. Amadei B, Urbani S, Cazaly A, Fiscaro P, Zerbini A, Ahmed P, et al. Activation of natural killer cells during acute infection with hepatitis C virus. *Gastroenterology*. 2010; 138(4):1536–1545. [PubMed: 20080094]
125. Pelletier S, Drouin C, Bedard N, Khakoo SI, Bruneau J, Shoukry NH. Increased degranulation of natural killer cells during acute HCV correlates with the magnitude of virus-specific T cell responses. *J Hepatol*. 2010; 53(5):805–816. [PubMed: 20688412]
126. Yoon JC, Shiina M, Ahlenstiel G, Rehermann B. Natural killer cell function is intact after direct exposure to infectious hepatitis C virions. *Hepatology*. 2009; 49(1):12–21. [PubMed: 19085909]
127. Edlich B, Ahlenstiel G, Zabaleta Azpiroz A, Stoltzfus J, Noureddin M, Serti E, et al. Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C patients. *Hepatology*. 2012; 55(1):39–48. [PubMed: 21898483]
128. Golden-Mason L, Rosen HR. Natural killer cells: multifaceted players with key roles in hepatitis C immunity. *Immunol Rev*. 2013; 255(1):68–81. [PubMed: 23947348]
129. Palucka K, Banchereau J. Human dendritic cell subsets in vaccination. *Curr Opin Immunol*. 2013; 25(3):396–402. [PubMed: 23725656]
130. Klechevsky E, Banchereau J. Human dendritic cells subsets as targets and vectors for therapy. *Ann N Y Acad Sci*. 2013; 1284:24–30. [PubMed: 23651190]
131. Pulendran B. The varieties of immunological experience: of pathogens, stress, and dendritic cells. *Annu Rev Immunol*. 2015; 33:563–606. [PubMed: 25665078]

132. Longman RS, Talal AH, Jacobson IM, Albert ML, Rice CM. Presence of functional dendritic cells in patients chronically infected with hepatitis C virus. *Blood*. 2004; 103(3):1026–1029. [PubMed: 14525790]
133. Longman RS, Talal AH, Jacobson IM, Rice CM, Albert ML. Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. *J Infect Dis*. 2005; 192(3):497–503. [PubMed: 15995965]
134. Albert ML, Decalf J, Pol S. Plasmacytoid dendritic cells move down on the list of suspects: in search of the immune pathogenesis of chronic hepatitis C. *J Hepatol*. 2008; 49(6):1069–1078. [PubMed: 18929418]
135. O'Connor KS, George J, Booth D, Ahlenstiel G. Dendritic cells in hepatitis C virus infection: key players in the IFNL3-genotype response. *World J Gastroenterol*. 2014; 20(47):17830–17838. [PubMed: 25548481]
136. Lai WK, Curbishley SM, Goddard S, Alabraba E, Shaw J, Youster J, et al. Hepatitis C is associated with perturbation of intrahepatic myeloid and plasmacytoid dendritic cell function. *J Hepatol*. 2007; 47(3):338–347. [PubMed: 17467113]
137. Rodrigue-Gervais IG, Jouan L, Beaulieu G, Sauve D, Bruneau J, Willems B, et al. Poly(I:C) and lipopolysaccharide innate sensing functions of circulating human myeloid dendritic cells are affected in vivo in hepatitis C virus-infected patients. *J Virol*. 2007; 81(11):5537–5546. [PubMed: 17376921]
138. Ryan EJ, Stevenson NJ, Hegarty JE, O'Farrelly C. Chronic hepatitis C infection blocks the ability of dendritic cells to secrete IFN-alpha and stimulate T-cell proliferation. *J Viral Hepat*. 2011; 18(12):840–851. [PubMed: 22093032]
139. Shiina M, Rehmann B. Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. *Hepatology*. 2007
140. Mellor J, Haydon G, Blair C, Livingstone W, Simmonds P. Low level or absent in vivo replication of hepatitis C virus and hepatitis G virus/GB virus C in peripheral blood mononuclear cells. *J Gen Virol*. 1998; 79(Pt 4):705–714. [PubMed: 9568964]
141. Lambotin M, Baumert TF, Barth H. Distinct intracellular trafficking of hepatitis C virus in myeloid and plasmacytoid dendritic cells. *J Virol*. 2010; 84(17):8964–8969. [PubMed: 20573834]
142. Lozach PY, Amara A, Bartosch B, Virelizier JL, Arenzana-Seisdedos F, Cosset FL, et al. C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles. *J Biol Chem*. 2004; 279(31):32035–32045. [PubMed: 15166245]
143. Lozach PY, Lortat-Jacob H, de Lacroix de Lavalette A, Staropoli I, Foug S, Amara A, et al. DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. *J Biol Chem*. 2003; 278(22):20358–20366. [PubMed: 12609975]
144. Pelletier S, Bedard N, Said E, Ancuta P, Bruneau J, Shoukry NH. Sustained hyperresponsiveness of dendritic cells is associated with spontaneous resolution of acute hepatitis C. *J Virol*. 2013; 87(12):6769–6781. [PubMed: 23576504]
145. Boltjes A, Movita D, Boonstra A, Woltman AM. The role of Kupffer cells in hepatitis B and hepatitis C virus infections. *J Hepatol*. 2014; 61(3):660–671. [PubMed: 24798624]
146. Shrivastava S, Mukherjee A, Ray R, Ray RB. Hepatitis C virus induces interleukin-1beta (IL-1beta)/IL-18 in circulatory and resident liver macrophages. *J Virol*. 2013; 87(22):12284–12290. [PubMed: 24006444]
147. Negash AA, Ramos HJ, Crochet N, Lau DT, Doehle B, Papic N, et al. IL-1beta production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. *PLoS Pathog*. 2013; 9(4):e1003330. [PubMed: 23633957]
148. Serti E, Werner JM, Chattergoon M, Cox AL, Lohmann V, Rehmann B. Monocytes activate natural killer cells via inflammasome-induced interleukin 18 in response to hepatitis C virus replication. *Gastroenterology*. 2014; 147(1):209–220. e3. [PubMed: 24685721]
149. Chattergoon MA, Latanich R, Quinn J, Winter ME, Buckheit RW 3rd, Blankson JN, et al. HIV and HCV activate the inflammasome in monocytes and macrophages via endosomal Toll-like receptors without induction of type 1 interferon. *PLoS Pathog*. 2014; 10(5):e1004082. [PubMed: 24788318]

150. Major ME, Dahari H, Mihalik K, Puig M, Rice CM, Neumann AU, et al. Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. *Hepatology*. 2004; 39(6):1709–1720. [PubMed: 15185313]
151. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. *J Clin Invest*. 2009; 119(7):1745–1754. [PubMed: 19587449]
152. Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. *Nat Med*. 2013; 19(7):859–868. [PubMed: 23836236]
153. Day CL, Lauer GM, Robbins GK, McGovern B, Wurcel AG, Gandhi RT, et al. Broad specificity of virus-specific CD4⁺ T-helper-cell responses in resolved hepatitis C virus infection. *J Virol*. 2002; 76(24):12584–12595. [PubMed: 12438584]
154. Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, et al. HCV persistence and immune evasion in the absence of memory T cell help. *Science*. 2003; 302(5645):659–662. [PubMed: 14576438]
155. Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, Reimann KA, et al. Memory CD8⁺ T cells are required for protection from persistent hepatitis C virus infection. *J Exp Med*. 2003; 197(12):1645–1655. [PubMed: 12810686]
156. Jo J, Aichele U, Kersting N, Klein R, Aichele P, Bisse E, et al. Analysis of CD8⁺ T-cell-mediated inhibition of hepatitis C virus replication using a novel immunological model. *Gastroenterology*. 2009; 136(4):1391–1401. [PubMed: 19185579]
157. Watanabe H, Wells F, Major ME. Clearance of hepatitis C in chimpanzees is associated with intrahepatic T-cell perforin expression during the late acute phase. *J Viral Hepat*. 2010; 17(4):245–253. [PubMed: 19709361]
158. Wherry EJ. T cell exhaustion. *Nat Immunol*. 2011; 12(6):492–499. [PubMed: 21739672]
159. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. *Journal of Experimental Medicine*. 2000; 191(9):1499–1512. [PubMed: 10790425]
160. Lanford RE, Guerra B, Chavez D, Bigger C, Brasky KM, Wang XH, et al. Cross-genotype immunity to hepatitis C virus. *J Virol*. 2004; 78(3):1575–1581. [PubMed: 14722311]
161. Bukh J, Thimme R, Meunier JC, Faulk K, Spangenberg HC, Chang KM, et al. Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. *J Virol*. 2008; 82(16):8183–8195. [PubMed: 18550671]
162. Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, et al. Lack of protective immunity against reinfection with hepatitis C virus. *Science*. 1992; 258(5079):135–140. [PubMed: 1279801]
163. Schulze Zur Wiesch J, Lauer GM, Timm J, Kuntzen T, Neukamm M, Berical A, et al. Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non-genotype 1 infection. *Blood*. 2007; 110(5):1559–1569. [PubMed: 17475911]
164. Park SH, Veerapu NS, Shin EC, Biancotto A, McCoy JP, Capone S, et al. Subinfectious hepatitis C virus exposures suppress T cell responses against subsequent acute infection. *Nat Med*. 2013; 19(12):1638–1642. [PubMed: 24270546]
165. Dahari H, Major M, Zhang X, Mihalik K, Rice CM, Perelson AS, et al. Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. *Gastroenterology*. 2005; 128(4):1056–1066. [PubMed: 15825086]
166. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. *J Exp Med*. 2001; 194(10):1395–1406. [PubMed: 11714747]
167. Klenerman P, Thimme R. T cell responses in hepatitis C: the good, the bad and the unconventional. *Gut*. 2012; 61(8):1226–1234. [PubMed: 21873736]
168. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. *Annu Rev Pathol Mech Dis*. 2006; 1:23–61.
169. Kakimi K, Lane TE, Wieland S, Asensio VC, Campbell IL, Chisari FV, et al. Blocking chemokine responsive to γ -2/interferon (IFN)- γ inducible protein and monokine induced by IFN- γ activity

in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. *J Exp Med*. 2001; 194(12):1755–1766. [PubMed: 11748277]

170. Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR, Rehermann B. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. *J Infect Dis*. 2012; 205(5):763–771. [PubMed: 22293431]
171. Callendret B, Walker C. A siege of hepatitis: immune boost for viral hepatitis. *Nat Med*. 2011; 17(3):252–253. [PubMed: 21383718]
172. Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut WW, Zachoval R, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4⁺ T-cell response in acute hepatitis C. *Gastroenterology*. 1999; 117(4):933–941. [PubMed: 10500077]
173. Schulze Zur Wiesch J, Ciuffreda D, Lewis-Ximenez L, Kasprovicz V, Nolan BE, Streeck H, et al. Broadly directed virus-specific CD4⁺ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence. *J Exp Med*. 2012; 209(1):61–75. [PubMed: 22213804]
174. Day CL, Seth NP, Lucas M, Appel H, Gauthier L, Lauer GM, et al. Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. *J Clin Invest*. 2003; 112(6):831–842. [PubMed: 12975468]
175. Welsh RM, Waggoner SN. NK cells controlling virus-specific T cells: Rheostats for acute vs. persistent infections. *Virology*. 2013; 435(1):37–45. [PubMed: 23217614]
176. Waggoner SN, Daniels KA, Welsh RM. Therapeutic depletion of natural killer cells controls persistent infection. *J Virol*. 2014; 88(4):1953–1960. [PubMed: 24284324]
177. Golden-Mason L, Burton JR Jr, Castelblanco N, Klarquist J, Benlloch S, Wang C, et al. Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence. *Hepatology*. 2006; 44(5):1098–1109. [PubMed: 17058243]
178. Boyman O, Krieg C, Homann D, Sprent J. Homeostatic maintenance of T cells and natural killer cells. *Cell Mol Life Sci*. 2012; 69(10):1597–1608. [PubMed: 22460580]
179. McMahan RH, Golden-Mason L, Nishimura MI, McMahon BJ, Kemper M, Allen TM, et al. Tim-3 expression on PD-1⁺ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. *J Clin Invest*. 2010; 120(12):4546–4557. [PubMed: 21084749]
180. Kasprovicz V, Schulze Zur Wiesch J, Kuntzen T, Nolan BE, Longworth S, Berical A, et al. High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8⁺ and CD4⁺ T cells during acute HCV infection, irrespective of clinical outcome. *J Virol*. 2008; 82(6):3154–3160. [PubMed: 18160439]
181. Raziorrouh B, Ulsenheimer A, Schraut W, Heeg M, Kurktschiev P, Zachoval R, et al. Inhibitory molecules that regulate expansion and restoration of HCV-specific CD4⁺ T cells in patients with chronic infection. *Gastroenterology*. 2011; 141(4):1422–1431. 31, e1–e6. [PubMed: 21763239]
182. Kared H, Fabre T, Bedard N, Bruneau J, Shoukry NH. Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C. *PLoS Pathog*. 2013; 9(6):e1003422. [PubMed: 23818845]
183. Fuller MJ, Shoukry NH, Gushima T, Bowen DG, Callendret B, Campbell KJ, et al. Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection. *Hepatology*. 2010; 51(2):378–387. [PubMed: 19918975]
184. Fleming VM, Harcourt G, Barnes E, Klenerman P. Virological footprint of CD4⁺ T-cell responses during chronic hepatitis C virus infection. *J Gen Virol*. 2010; 91(Pt 6):1396–1406. [PubMed: 20107020]
185. Bengsch B, Seigel B, Ruhl M, Timm J, Kuntz M, Blum HE, et al. Coexpression of PD-1, 2B4, CD160 and KLRG1 on exhausted HCV-specific CD8⁺ T cells is linked to antigen recognition and T cell differentiation. *PLoS Pathog*. 2010; 6(6):e1000947. [PubMed: 20548953]
186. Radziewicz H, Ibegbu CC, Fernandez ML, Workowski KA, Obideen K, Wehbi M, et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. *J Virol*. 2007; 81(6):2545–2553. [PubMed: 17182670]

187. Golden-Mason L, Palmer BE, Kassam N, Townshend-Bulson L, Livingston S, McMahon BJ, et al. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. *J Virol*. 2009; 83(18):9122–9130. [PubMed: 19587053]
188. Kroy DC, Ciuffreda D, Cooperrider JH, Tomlinson M, Hauck GD, Aneja J, et al. Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors. *Gastroenterology*. 2014; 146(2):550–561. [PubMed: 24148617]
189. Zhang N, Bevan MJ. CD8(+) T cells: foot soldiers of the immune system. *Immunity*. 2011; 35(2): 161–168. [PubMed: 21867926]
190. Cox MA, Harrington LE, Zajac AJ. Cytokines and the inception of CD8 T cell responses. *Trends Immunol*. 2011; 32(4):180–186. [PubMed: 21371940]
191. Shin EC, Park SH, Nascimbeni M, Major M, Caggiari L, de Re V, et al. The frequency of CD127(+) hepatitis C virus (HCV)-specific T cells but not the expression of exhaustion markers predicts the outcome of acute HCV infection. *J Virol*. 2013; 87(8):4772–4777. [PubMed: 23388706]
192. Abdel-Hakeem MS, Bedard N, Murphy D, Bruneau J, Shoukry NH. Signatures of protective memory immune responses during hepatitis C virus reinfection. *Gastroenterology*. 2014; 147(4): 870–881. e8. [PubMed: 25038432]
193. Radziewicz H, Ibegbu CC, Hon H, Osborn MK, Obideen K, Wehbi M, et al. Impaired hepatitis C virus (HCV)-specific effector CD8+ T cells undergo massive apoptosis in the peripheral blood during acute HCV infection and in the liver during the chronic phase of infection. *J Virol*. 2008; 82(20):9808–9822. [PubMed: 18667503]
194. Park SH, Shin EC, Capone S, Caggiari L, De Re V, Nicosia A, et al. Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus. *Gastroenterology*. 2012; 143(4):1048–1060. e4. [PubMed: 22705008]
195. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. *Nature*. 2006; 439(7077):682–687. [PubMed: 16382236]
196. Frebel H, Nindl V, Schuepbach RA, Braunschweiler T, Richter K, Vogel J, et al. Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice. *J Exp Med*. 2012; 209(13):2485–2499. [PubMed: 23230000]
197. Frebel H, Oxenius A. The risks of targeting co-inhibitory pathways to modulate pathogen-directed T cell responses. *Trends Immunol*. 2013; 34(5):193–199. [PubMed: 23333205]
198. Bowen DG, Shoukry NH, Grakoui A, Fuller MJ, Cawthon AG, Dong C, et al. Variable patterns of programmed death-1 expression on fully functional memory T cells after spontaneous resolution of hepatitis C virus infection. *J Virol*. 2008; 82(10):5109–5114. [PubMed: 18337576]
199. Nakamoto N, Kaplan DE, Coleclough J, Li Y, Valiga ME, Kaminski M, et al. Functional Restoration of HCV-Specific CD8 T Cells by PD-1 Blockade Is Defined by PD-1 Expression and Compartmentalization. *Gastroenterology*. 2008; 134(7):1927–1937. e2. [PubMed: 18549878]
200. Fuller MJ, Callendret B, Zhu B, Freeman GJ, Hasselschwert DL, Satterfield W, et al. Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). *Proc Natl Acad Sci U S A*. 2013; 110(37):15001–15006. [PubMed: 23980172]
201. Nakamoto N, Cho H, Shaked A, Olthoff K, Valiga ME, Kaminski M, et al. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. *PLoS Pathog*. 2009; 5(2):e1000313. [PubMed: 19247441]
202. Rong L, Dahari H, Ribeiro RM, Perelson AS. Rapid emergence of protease inhibitor resistance in hepatitis C virus. *Science translational medicine*. 2010; 2(30):30ra2.
203. Stoddard MB, Li H, Wang S, Saeed M, Andrus L, Ding W, et al. Identification, molecular cloning, and analysis of full-length hepatitis C virus transmitted/founder genotypes 1, 3, and 4. *MBio*. 2015; 6(2):e02518. [PubMed: 25714714]
204. Cox AL, Mosbruger T, Mao Q, Liu Z, Wang XH, Yang HC, et al. Cellular immune selection with hepatitis C virus persistence in humans. *J Exp Med*. 2005; 201(11):1741–1752. [PubMed: 15939790]

205. Soderholm J, Ahlen G, Kaul A, Frelin L, Alheim M, Barnfield C, et al. Relation between viral fitness and immune escape within the hepatitis C virus protease. *Gut*. 2006; 55(2):266–274. [PubMed: 16105887]
206. Neumann-Haefelin C, Killinger T, Timm J, Southwood S, McKinney D, Blum HE, et al. Absence of viral escape within a frequently recognized HLA-A26-restricted CD8+ T-cell epitope targeting the functionally constrained hepatitis C virus NS5A/5B cleavage site. *J Gen Virol*. 2007; 88(Pt 7):1986–1991. [PubMed: 17554032]
207. Uebelhoefer L, Han JH, Callendret B, Mateu G, Shoukry NH, Hanson HL, et al. Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness. *PLoS Pathog*. 2008; 4(9):e1000143. [PubMed: 18773115]
208. Dazert E, Neumann-Haefelin C, Bressanelli S, Fitzmaurice K, Kort J, Timm J, et al. Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response. *J Clin Invest*. 2009; 119(2):376–386. [PubMed: 19139562]
209. Pfafferoth K, Gaudieri S, Ulsenheimer A, James I, Heeg M, Nolan D, et al. Constrained pattern of viral evolution in acute and early HCV infection limits viral plasticity. *PLoS ONE*. 2011; 6(2):e16797. [PubMed: 21347433]
210. Kuntzen T, Timm J, Berical A, Lewis-Ximenez LL, Jones A, Nolan B, et al. Viral sequence evolution in acute hepatitis C virus infection. *J Virol*. 2007; 81(21):11658–11668. [PubMed: 17699568]
211. Erickson AL, Kimura Y, Igarashi S, Eichelberger J, Houghton M, Sidney J, et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. *Immunity*. 2001; 15(6):883–895. [PubMed: 11754811]
212. Callendret B, Bukh J, Eccleston HB, Heksche R, Hasselschwert DL, Purcell RH, et al. Transmission of clonal hepatitis C virus genomes reveals the dominant but transitory role of CD8(+) T cells in early viral evolution. *J Virol*. 2011; 85(22):11833–11845. [PubMed: 21900166]
213. von Hahn T, Yoon JC, Alter H, Rice CM, Rehmann B, Balfe P, et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. *Gastroenterology*. 2007; 132(2):667–678. [PubMed: 17258731]
214. Bailey JR, Wasilewski LN, Snider AE, El-Diwanly R, Osburn WO, Keck Z, et al. Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance. *J Clin Invest*. 2015; 125(1):437–447. [PubMed: 25500884]
215. Timm J, Lauer GM, Kavanagh DG, Sheridan I, Kim AY, Lucas M, et al. CD8 epitope escape and reversion in acute HCV infection. *J Exp Med*. 2004; 200(12):1593–1604. [PubMed: 15611288]
216. Tester I, Smyk-Pearson S, Wang P, Wertheimer A, Yao E, Lewinsohn DM, et al. Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. *J Exp Med*. 2005; 201(11):1725–1731. [PubMed: 15939788]
217. Komatsu H, Lauer G, Pybus OG, Ouchi K, Wong D, Ward S, et al. Do antiviral CD8+ T cells select hepatitis C virus escape mutants? Analysis in diverse epitopes targeted by human intrahepatic CD8+ T lymphocytes. *J Viral Hepat*. 2006; 13(2):121–130. [PubMed: 16436130]
218. Neumann-Haefelin C, McKiernan S, Ward S, Viazov S, Spangenberg HC, Killinger T, et al. Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. *Hepatology*. 2006; 43(3):563–572. [PubMed: 16496339]
219. Fitzmaurice K, Petrovic D, Ramamurthy N, Simmons R, Merani S, Gaudieri S, et al. Molecular footprints reveal the impact of the protective HLA-A*03 allele in hepatitis C virus infection. *Gut*. 2011; 60(11):1563–1571. [PubMed: 21551190]
220. Merani S, Petrovic D, James I, Chopra A, Cooper D, Freitas E, et al. Effect of immune pressure on hepatitis C virus evolution: insights from a single-source outbreak. *Hepatology*. 2011; 53(2): 396–405. [PubMed: 21246583]
221. Meyer-Olson D, Shoukry NH, Brady KW, Kim H, Olson DP, Hartman K, et al. Limited T cell receptor diversity of HCV-specific T cell responses is associated with CTL escape. *J Exp Med*. 2004; 200(3):307–319. [PubMed: 15289502]

222. Wolfl M, Rutebemberwa A, Mosbrugger T, Mao Q, Li HM, Netski D, et al. Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire. *J Immunol.* 2008; 181(9):6435–6446. [PubMed: 18941234]
223. Honegger JR, Kim S, Price AA, Kohout JA, McKnight KL, Prasad MR, et al. Loss of immune escape mutations during persistent HCV infection in pregnancy enhances replication of vertically transmitted viruses. *Nat Med.* 2013; 19(11):1529–1533. [PubMed: 24162814]
224. Urbani S, Amadei B, Cariani E, Fisicaro P, Orlandini A, Missale G, et al. The impairment of CD8 responses limits the selection of escape mutations in acute hepatitis C virus infection. *Journal of Immunology.* 2005; 175(11):7519–7529.
225. Rutebemberwa A, Ray SC, Astemborski J, Levine J, Liu L, Dowd KA, et al. High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection. *J Immunol.* 2008; 181(12):8215–8225. [PubMed: 19050238]
226. Chang KM, Rehmann B, McHutchison JG, Pasquinelli C, Southwood S, Sette A, et al. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. *J Clin Invest.* 1997; 100(9):2376–2385. [PubMed: 9410918]
227. Ulsenheimer A, Paranhos-Baccala G, Komurian-Pradel F, Raziorrouh B, Kurtschiev P, Diepolder HM, et al. Lack of variant specific CD8+ T-cell response against mutant and pre-existing variants leads to outgrowth of particular clones in acute hepatitis C. *Viro J.* 2013; 10:295. [PubMed: 24073713]
228. Fernandez J, Taylor D, Morhardt DR, Mihalik K, Puig M, Rice CM, et al. Long-term persistence of infection in chimpanzees inoculated with an infectious hepatitis C virus clone is associated with a decrease in the viral amino acid substitution rate and low levels of heterogeneity. *J Virol.* 2004; 78(18):9782–9789. [PubMed: 15331711]
229. Kasprovicz V, Kang YH, Lucas M, Schulze Zur Wiesch J, Kuntzen T, Fleming V, et al. Hepatitis C virus (HCV) sequence variation induces an HCV-specific T-cell phenotype analogous to spontaneous resolution. *J Virol.* 2010; 84(3):1656–1663. [PubMed: 19906915]
230. Cashman SB, Marsden BD, Dustin LB. The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. *Frontiers in immunology.* 2014; 5:550. [PubMed: 25426115]
231. Ball JK, Tarr AW, McKeating JA. The past, present and future of neutralizing antibodies for hepatitis C virus. *Antiviral Res.* 2014; 105:100–111. [PubMed: 24583033]
232. Netski DM, Mosbrugger T, Depla E, Maertens G, Ray SC, Hamilton RG, et al. Humoral immune response in acute hepatitis C virus infection. *Clin Infect Dis.* 2005; 41(5):667–675. [PubMed: 16080089]
233. Dustin LB, Charles ED. Primary, post-primary and non-specific immunoglobulin M responses in HCV infection. *Antivir Ther.* 2012; 17(7 Pt B):1449–1452. [PubMed: 23322600]
234. Bassett SE, Thomas DL, Brasky KM, Lanford RE. Viral persistence, antibody to E1 and E2, and hypervariable region 1 sequence stability in hepatitis C virus-inoculated chimpanzees. *J Virol.* 1999; 73(2):1118–1126. [PubMed: 9882313]
235. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, et al. Analysis of a successful immune response against hepatitis C virus. *Immunity.* 1999; 10(4):439–449. [PubMed: 10229187]
236. Razvi S, Schneider L, Jonas MM, Cunningham-Rundles C. Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency. *Clin Immunol.* 2001; 101(3):284–288. [PubMed: 11726220]
237. Logvinoff C, Major ME, Oldach D, Heyward S, Talal A, Balfe P, et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. *Proc Natl Acad Sci U S A.* 2004; 101(27):10149–10154. [PubMed: 15220475]
238. Major ME, Mihalik K, Puig M, Rehmann B, Nascimbeni M, Rice CM, et al. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. *J Virol.* 2002; 76(13):6586–6595. [PubMed: 12050371]
239. Barth H, Rybczynska J, Patient R, Choi Y, Sapp RK, Baumert TF, et al. Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees. *Hepatology.* 2011; 54(4):1135–1148. [PubMed: 21674561]

240. Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. *Nat Med.* 2000; 6(5):578–582. [PubMed: 10802716]
241. Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, Cosset FL, et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. *Proc Natl Acad Sci U S A.* 2007; 104(14):6025–6030. [PubMed: 17392433]
242. Catanese MT, Dorner M. Advances in experimental systems to study hepatitis C virus in vitro and in vivo. *Virology.* 2015; 479–480C:221–233.
243. Bartosch B, Bukh J, Meunier JC, Granier C, Engle RE, Blackwelder WC, et al. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. *Proc Natl Acad Sci U S A.* 2003; 100(24):14199–14204. [PubMed: 14617769]
244. Kaplan DE, Sugimoto K, Newton K, Valiga ME, Ikeda F, Aytaman A, et al. Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. *Gastroenterology.* 2007; 132(2):654–666. [PubMed: 17258733]
245. Pedersen J, Carlsen TH, Prentoe J, Ramirez S, Jensen TB, Fornis X, et al. Neutralization resistance of hepatitis C virus can be overcome by recombinant human monoclonal antibodies. *Hepatology.* 2013; 58(5):1587–1597. [PubMed: 23729237]
246. Morin TJ, Broering TJ, Leav BA, Blair BM, Rowley KJ, Boucher EN, et al. Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. *PLoS Pathog.* 2012; 8(8):e1002895. [PubMed: 22952447]
247. Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, et al. Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. *Proceedings of the National Academy of Sciences of the United States of America.* 1994; 91(16):7792–7796. [PubMed: 7519785]
248. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. *Nat Med.* 2007
249. Vanwolleghem T, Bukh J, Meuleman P, Desombere I, Meunier JC, Alter H, et al. Polyclonal immunoglobulins from a chronic hepatitis C virus patient protect human liver-chimeric mice from infection with a homologous hepatitis C virus strain. *Hepatology.* 2008; 47(6):1846–1855. [PubMed: 18452146]
250. de Jong YP, Dorner M, Mommersteeg MC, Xiao JW, Balazs AB, Robbins JB, et al. Broadly neutralizing antibodies abrogate established hepatitis C virus infection. *Science translational medicine.* 2014; 6(254):254ra129.
251. Dorner M, Horwitz JA, Robbins JB, Barry WT, Feng Q, Mu K, et al. A genetically humanized mouse model for hepatitis C virus infection. *Nature.* 2011; 474(7350):208–211. [PubMed: 21654804]
252. Dorner M, Horwitz JA, Donovan BM, Labitt RN, Budell WC, Friling T, et al. Completion of the entire hepatitis C virus life cycle in genetically humanized mice. *Nature.* 2013; 501(7466):237–241. [PubMed: 23903655]
253. Osburn WO, Snider AE, Wells BL, Latanich R, Bailey JR, Thomas DL, et al. Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. *Hepatology.* 2014; 59(6):2140–2151. [PubMed: 24425349]
254. Dowd KA, Netski DM, Wang XH, Cox AL, Ray SC. Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. *Gastroenterology.* 2009; 136(7):2377–2386. [PubMed: 19303013]
255. Esteban-Riesco L, Depaulis F, Moreau A, Bacq Y, Dubois F, Goudeau A, et al. Rapid and sustained autologous neutralizing response leading to early spontaneous recovery after HCV infection. *Virology.* 2013; 444(1–2):90–99. [PubMed: 23890816]
256. Keck ZY, Li SH, Xia J, von Hahn T, Balfe P, McKeating JA, et al. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. *J Virol.* 2009; 83(12):6149–6160. [PubMed: 19321602]
257. Farci P, Alter HJ, Wong DCHMR, Govindarajan S, Engle R, et al. Prevention of hepatitis C virus infection in chimpanzee after antibody-mediated in vitro neutralization. *Proc Natl Acad Sci U S A.* 1994; 91:7792–7796. [PubMed: 7519785]

258. Yu, M-yW, Bartosch, B., Zhang, P., Guo, Z-p, Renzi, PM., Shen, L-m, et al. Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. *Proc Natl Acad Sci U S A.* 2004; 101(20):7705–7710. [PubMed: 15136748]
259. Wahid A, Dubuisson J. Virus-neutralizing antibodies to hepatitis C virus. *J Viral Hepat.* 2013; 20(6):369–376. [PubMed: 23647953]
260. Bailey JR, Dowd KA, Snider AE, Osburn WO, Mehta SH, Kirk GD, et al. CD4+ T-Cell-Dependent Reduction in Hepatitis C Virus-Specific Neutralizing Antibody Responses After Coinfection With Human Immunodeficiency Virus. *J Infect Dis.* 2015
261. Zhang P, Wu CG, Mihalik K, Virata-Theimer ML, Yu MY, Alter HJ, et al. Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. *Proc Natl Acad Sci U S A.* 2007; 104(20):8449–8454. [PubMed: 17494735]
262. Zhang P, Zhong L, Struble EB, Watanabe H, Kachko A, Mihalik K, et al. Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. *Proc Natl Acad Sci U S A.* 2009; 106(18):7537–7541. [PubMed: 19380744]
263. Keck Z, Wang W, Wang Y, Lau P, Carlsen TH, Prentoe J, et al. Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. *J Virol.* 2013; 87(1):37–51. [PubMed: 23097455]
264. Duan H, Kachko A, Zhong L, Struble E, Pandey S, Yan H, et al. Amino acid residue-specific neutralization and nonneutralization of hepatitis C virus by monoclonal antibodies to the E2 protein. *J Virol.* 2012; 86(23):12686–12694. [PubMed: 22973024]
265. Tarr AW, Urbanowicz RA, Jayaraj D, Brown RJ, McKeating JA, Irving WL, et al. Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. *Journal of virology.* 2012; 86(5):2739–2749. [PubMed: 22171278]
266. Zhang LF, Zheng SG, Li F. [Auto-antibodies in hepatitis C virus infection]. *Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.* 2009; 17(10):788–789. [PubMed: 19874699]
267. Lapierre P, Troesch M, Alvarez F, Soudeyns H. Structural basis for broad neutralization of hepatitis C virus quasiespecies. *PloS one.* 2011; 6(10):e26981. [PubMed: 22046426]
268. Sautto G, Mancini N, Diotti RA, Solfrosi L, Clementi M, Burioni R. Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference. *Antiviral research.* 2012; 96(1):82–89. [PubMed: 22898087]
269. Helle F, Duverlie G, Dubuisson J. The hepatitis C virus glycan shield and evasion of the humoral immune response. *Viruses.* 2011; 3(10):1909–1932. [PubMed: 22069522]
270. Catanese MT, Uryu K, Kopp M, Edwards TJ, Andrus L, Rice WJ, et al. Ultrastructural analysis of hepatitis C virus particles. *Proc Natl Acad Sci U S A.* 2013; 110(23):9505–9510. [PubMed: 23690609]
271. Brimacombe CL, Grove J, Meredith LW, Hu K, Syder AJ, Flores MV, et al. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. *J Virol.* 2011; 85(1):596–605. [PubMed: 20962076]
272. Timpe JM, Stamatakis Z, Jennings A, Hu K, Farquhar MJ, Harris HJ, et al. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. *Hepatology.* 2008; 47(1):17–24. [PubMed: 17941058]
273. Liang Y, Shilagard T, Xiao SY, Snyder N, Lau D, Cicalese L, et al. Visualizing hepatitis C virus infections in human liver by two-photon microscopy. *Gastroenterology.* 2009; 137(4):1448–1458. [PubMed: 19632233]
274. Ramakrishnaiah V, Thumann C, Fofana I, Habersetzer F, Pan Q, de Ruiter PE, et al. Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells. *Proc Natl Acad Sci U S A.* 2013; 110(32):13109–13113. [PubMed: 23878230]
275. Catanese MT, Loureiro J, Jones CT, Dorner M, von Hahn T, Rice CM. Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission. *J Virol.* 2013; 87(15):8282–8293. [PubMed: 23698298]

276. Tarr AW, Lafaye P, Meredith L, Damier-Piolle L, Urbanowicz RA, Meola A, et al. An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission. *Hepatology*. 2013; 58(3): 932–939. [PubMed: 23553604]
277. Bankwitz D, Steinmann E, Bitzegeio J, Ciesek S, Friesland M, Herrmann E, et al. Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. *J Virol*. 2010; 84(11):5751–5763. [PubMed: 20357091]
278. Prentoe J, Jensen TB, Meuleman P, Serre SB, Scheel TK, Leroux-Roels G, et al. Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. *J Virol*. 2011; 85(5):2224–2234. [PubMed: 21123377]
279. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. *Science*. 2000; 288(5464):339–344. [PubMed: 10764648]
280. Liu L, Fisher BE, Dowd KA, Astemborski J, Cox AL, Ray SC. Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection. *J Virol*. 2010; 84(10):5067–5077. [PubMed: 20200239]
281. Booth JC, Kumar U, Webster D, Monjardino J, Thomas HC. Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. *Hepatology*. 1998; 27(1):223–227. [PubMed: 9425941]
282. Lee WM, Polson JE, Carney DS, Sahin B, Gale M Jr. Reemergence of hepatitis C virus after 8.5 years in a patient with hypogammaglobulinemia: evidence for an occult viral reservoir. *J Infect Dis*. 2005; 192(6):1088–1092. [PubMed: 16107964]
283. Gaud U, Langer B, Petropoulou T, Thomas HC, Karayiannis P. Changes in hypervariable region 1 of the envelope 2 glycoprotein of hepatitis C virus in children and adults with humoral immune defects. *J Med Virol*. 2003; 69(3):350–356. [PubMed: 12526045]
284. Kong L, Giang E, Nieusma T, Kadam RU, Cogburn KE, Hua Y, et al. Hepatitis C virus E2 envelope glycoprotein core structure. *Science*. 2013; 342(6162):1090–1094. [PubMed: 24288331]
285. Goffard A, Callens N, Bartosch B, Wychowski C, Cosset FL, Montpellier C, et al. Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. *J Virol*. 2005; 79(13): 8400–8409. [PubMed: 15956584]
286. Helle F, Vieyres G, Elkrief L, Popescu CI, Wychowski C, Descamps V, et al. Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. *J Virol*. 2010; 84(22):11905–11915. [PubMed: 20844034]
287. Falkowska E, Kajumo F, Garcia E, Reinus J, Dragic T. Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. *J Virol*. 2007; 81(15):8072–8079. [PubMed: 17507469]
288. Helle F, Goffard A, Morel V, Duverlie G, McKeating J, Keck ZY, et al. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. *J Virol*. 2007; 81(15):8101–8111. [PubMed: 17522218]
289. Mayo MJ. Extrahepatic manifestations of hepatitis C infection. *Am J Med Sci*. 2003; 325(3):135–148. [PubMed: 12640289]
290. Giordano TP, Henderson L, Landgren O, Chiao EY, Kramer JR, El-Serag H, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. *JAMA*. 2007; 297(18):2010–2017. [PubMed: 17488966]
291. Charles ED, Dustin LB. Hepatitis C virus-induced cryoglobulinemia. *Kidney Int*. 2009; 76:818–824. [PubMed: 19606079]
292. Ramos-Casals M, Stone JH, Cid MC, Bosch X. The cryoglobulinaemias. *Lancet*. 2012; 379(9813):348–360. [PubMed: 21868085]
293. Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. *J Hepatol*. 2013; 59(1):169–177. [PubMed: 23542089]

294. Charles ED, Green RM, Marukian S, Talal AH, Lake-Bakaar GV, Jacobson IM, et al. Clonal expansion of IgM+CD27+ B cells in HCV-associated mixed cryoglobulinemia. *Blood*. 2008; 111:1344–1356. [PubMed: 17942751]
295. Visentini M, Conti V, Cristofaletti C, Lazzeri C, Marrapodi R, Russo G, et al. Clonal expansion and functional exhaustion of monoclonal marginal zone B cells in mixed cryoglobulinemia: the yin and yang of HCV-driven lymphoproliferation and autoimmunity. *Autoimmunity reviews*. 2013; 12(3):430–435. [PubMed: 22940579]
296. Charles ED, Brunetti C, Marukian S, Ritola KD, Talal AH, Marks K, et al. Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21^{low} B-cell subset. *Blood*. 2011; 117(20):5425–5437. [PubMed: 21421840]
297. Chan CH, Hadlock KG, Fount SK, Levy S. V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. *Blood*. 2001; 97(4):1023–1026. [PubMed: 11159532]
298. Marasca R, Vaccari P, Luppi M, Zucchini P, Castelli I, Barozzi P, et al. Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma. *Am J Pathol*. 2001; 159(1): 253–261. [PubMed: 11438472]
299. De Re V, De Vita S, Marzotto A, Gloghini A, Pivetta B, Gasparotto D, et al. Pre-malignant and malignant lymphoproliferations in an HCV-infected type II mixed cryoglobulinemic patient are sequential phases of an antigen-driven pathological process. *Intl J Cancer*. 2000; 87(2):211–216.
300. Terrier B, Joly F, Vazquez T, Benech P, Rosenzweig M, Carpentier W, et al. Expansion of functionally anergic CD21-/low marginal zone-like B cell clones in hepatitis C virus infection-related autoimmunity. *J Immunol*. 2011; 187(12):6550–6563. [PubMed: 22084433]
301. Ivanovski M, Silvestri F, Pozzato G, Anand S, Mazzaro C, Burrone OR, et al. Somatic hypermutation, clonal diversity, and preferential expression of the V_H 51p1/V_L kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. *Blood*. 1998; 91(7):2433–2442. [PubMed: 9516143]
302. Rosa D, Saletti G, De Gregorio E, Zorat F, Comar C, D'Oro U, et al. Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. *Proc Natl Acad Sci U S A*. 2005; 102(51):18544–18549. [PubMed: 16339892]
303. Sung VM, Shimodaira S, Doughty AL, Picchio GR, Can H, Yen TS, et al. Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. *J Virol*. 2003; 77(3):2134–2146. [PubMed: 12525648]
304. McKeating JA, Zhang LQ, Logvinoff C, Flint M, Zhang J, Yu J, et al. Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81 dependent manner. *J Virol*. 2004; 78(16):8496–8505. [PubMed: 15280458]
305. Zehender G, Meroni L, De Maddalena C, Varchetta S, Monti G, Galli M. Detection of hepatitis C virus RNA in CD19 peripheral blood mononuclear cells of chronically infected patients. *J Infect Dis*. 1997; 176(5):1209–1214. [PubMed: 9359720]
306. Pham TN, King D, Macparland SA, McGrath JS, Reddy SB, Bursey FR, et al. Hepatitis C virus replicates in the same immune cell subsets in chronic hepatitis C and occult infection. *Gastroenterology*. 2008; 134(3):812–822. [PubMed: 18243182]
307. Veerapu NS, Raghuraman S, Liang TJ, Heller T, Rehmann B. Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses. *Gastroenterology*. 2011; 140(2):676–685. e1. [PubMed: 21040725]
308. Charles ED, Orloff MI, Nishiuchi E, Marukian S, Rice CM, Dustin LB. Somatic hypermutations confer rheumatoid factor activity in hepatitis C virus-associated mixed cryoglobulinemia. *Arthritis Rheum*. 2013; 65(9):2430–2440. [PubMed: 23754128]
309. Zignego AL, Wojcik GL, Cacoub P, Visentini M, Casato M, Mangia A, et al. Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. *Genes and immunity*. 2014; 15(7):500–505. [PubMed: 25030430]
310. Sène D, Limal N, Ghillani-Dalbin P, Saadoun D, Piette JC, Cacoub P. Hepatitis C virus-associated B-cell proliferation--the role of serum B lymphocyte stimulator (BLyS/BAFF). *Rheumatology (Oxford)*. 2007; 46(1):65–69. [PubMed: 16782735]

311. Halliday J, Klenerman P, Barnes E. Vaccination for hepatitis C virus: closing in on an evasive target. *Expert Rev Vaccines*. 2011; 10(5):659–672. [PubMed: 21604986]
312. Barth H. Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. *World J Hepatol*. 2015; 7(5):725–737. [PubMed: 25914773]
313. Swadling L, Capone S, Antrobus RD, Brown A, Richardson R, Newell EW, et al. A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory. *Science translational medicine*. 2014; 6(261): 261ra153.
314. Kelly C, Swadling L, Brown A, Capone S, Folgori A, Salio M, et al. Cross-reactivity of hepatitis C virus specific vaccine-induced T cells at immunodominant epitopes. *Eur J Immunol*. 2015; 45(1):309–316. [PubMed: 25263407]

Figure 1. HCV RNA and polyprotein. Conserved RNA structures in the 5' and 3' untranslated regions (UTR) are illustrated. The genome has a single long reading frame encoding a viral polyprotein of approximately 3000 amino acids. The polyprotein is processed co- and post-translationally by host and viral proteases to release the three structural proteins, Core, E1, and E2 (labeled in blue) and the seven non-structural proteins (labeled in red).

B **Figure 2.**

Innate immune activation by HCV RNA. A) RIG-I binds to PAMPs in HCV RNA and changes its conformation, activating one or more E3 ubiquitin ligases (yellow shapes). Ubiquitinated RIG-I may activate MAVS, which then forms prion-like aggregates that recruit additional ubiquitin ligases. Recent evidence suggests that MAVS on peroxisomes is particularly important for induction of IFN λ . Subsequent ubiquitination steps stimulate recruitment of enzymes that activate the downstream IRF3 and NF κ B pathways. HCV's NS3/4A protease can disable this pathway by cleaving MAVS near its transmembrane domain. B) TLR3 recognizes dsRNA within endosomal compartments, signaling via the adaptor, TRIF. TRIF stimulates ubiquitin-conjugating enzymes, resulting in recruitment of

enzymes that activate the IRF3 and NF κ B transcription factors. HCV's NS3-4A protease can disable TLR3 signaling by cleaving TRIF.

Figure 3.

T cell responses in acute resolving (A–B) and chronic (C–D) HCV infection. A) Patterns of viremia (HCV RNA) and liver cell death (alanine aminotransferase, ALT, which is released from damaged hepatocytes) in spontaneous resolution of HCV infection. B) CD4+ and CD8+ T cells respond to multiple HCV epitopes until viremia is cleared and afterwards. C) Patterns of viremia and liver cell death in chronic infection. D) CD4+ and CD8+ T cell responses wane as viremia persists. CD8+ T cells lose function due to exhaustion after loss of CD4+ T cell help. CD8+ T cells also select for variant virus sequences that escape immune detection.

Figure 4.

Humoral immune responses in acute resolving (A) and chronic (B) HCV infection. A) Rapid development of HCV-specific nAb may contribute to spontaneous resolution of infection. Ab to HCV structural and non-structural proteins can be detected by enzyme-linked immunoassay (EIA). Ab levels may decline after infection is cleared. B) Slower development of nAb responses may predispose to chronic infection. Ab to structural and non-structural proteins is detectable by EIA.